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Summary 
The purpose of this thesis is to identify and examine the molecular 
mechanisms which result in deficiency of the complement terminal pathway, a 
part of the innate immune system which can destroy pathogens by lysis 
through formation of the membrane attack complex (MAC). Patient samples 
with mutations in components C5, C7 and C8 were available and methods to 
study these mutations in either genomic, RNA or protein were developed. 
Work on C5 Deficiency focused on a young African Xhosa woman with C5 
deficiency, and identified a known nonsense mutation in exon 1 [c.84C>T; 
p.Q28X] and a novel missense mutation in exon 7 [c.754G>A] that leads to a 
conservative change [p.A252T]. Three intronic sequence variations were also 
identified. An in silico analysis of these mutations was made and a method for 
amplifying full length cDNA was developed. 
C7 Deficiency studies focused on four Irish families for which a large genomic 
deletion was thought to be present. Mapping of the breakpoints and PCR 
across the deletion identified a 6.4kb deletion together with the insertion of a 
novel 8bp sequence [c.739+1262_1270-2387delinsGCAGGCCA]. A method 
for carrier detection was developed. Bioinformatics analysis indicated that the 
initial DNA breakage was Alu-mediated. 
C8 Deficiency was investigated in three patients with C8 deficiency. 
Genomic studies revealed that two patients were shown to be homozygous 
for the common nonsense mutation in exon 9 [1282C > T; p.A428X. The other 
was a compound heterozygote for a novel duplication in exon 7 [c.1047_1053 
dupGGCTGTG], and a previously reported nonsense mutation [c.298C > T; 
p.G91X] in exon 3.  
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Introduction 
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1.1 A History of the Complement System 
The complement system is an essential part of the innate immune system and 
plays a significant role in host defence (Lambris JD., 1998). 
In the late 19th century experiments with serum demonstrated the presence of 
an unknown component which could lyse bacteria.  
Then, in 1896 a Belgian scientist, Jules Bordet, noted that whilst working with 
immunised animals that this unknown component could be further subdivided 
into two further categories.  Using guinea pigs immunised with Vibrio 
cholerae, Bordet demonstrated that heat inactivated serum from immunised 
animals could have lytic activity restored following reconstitution with serum 
from guinea pigs that had not been immunised.  
Therefore he surmised that two components are present, with one component 
losing it's lytic activity after heat treatment and showing no capability to adapt. 
It was Paul Ehrlich who first used the term „complement‟ after proposing that 
the component of serum which can be heat inactivated „complements‟ the 
activity of what Ehrlich described as amboreceptors, which we now know of 
as antibodies.  
The nature of complement was still a source of disagreement. Paul Ehrlich 
believed that each amboreceptor had a unique complement specific to the 
amboreceptor, whilst Jules Bordet believed that there was only one type of 
complement which could react with all amboreceptors.  
The debate continued until it was noted that complement was capable of 
acting in combination with specific antibodies, or in an antibody independent 
manner, which was considered a clear indication that there was one form of 
complement. 
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1.2  The Complement System  
 
The complement system, illustrated in figure 1, consists of approximately 30 
proteins and is traditionally thought of as a system that forms a cascade to 
recognise and destroy pathogens. The ability to destroy pathogens is only one 
of several functional roles of complement 
 
 
Figure 1. The complement system, taken from Gasque et al., expert reviews in molecular 
medicine 2003 
 
These complement proteins are abundant and can be found freely circulating 
in the blood, and they can comprise around 4% of the total blood protein 
(Morgan and Gasque., 1997). The complement system is activated by several 
mechanisms, including the binding of C1q to Fc regions of immunoglobulins.   
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Following activation enzymes quickly cleave specific components to initiate 
the complement cascade (Lambris et al., 1998).  
This then results in a comparatively large amplification of the cascade which 
in turn results in the formation of the membrane attack complex and then lysis 
of the target cell (Podack et al., 1984b).  
Although other factors such as thrombin may lead to complement activation 
(Amara et al., 2010), the three main biochemical pathways that activate the 
complement system are the classical, alternative and mannose-binding lectin 
pathway (Morgan and Gasque., 1997). 
The complement system performs several functions which can generally be 
described as; 
Lysis: The formation of the membrane attack complex can result in the lysis 
of bacteria, damaged or infected cells and viruses (Cole and Morgan., 2003). 
Opsonisation: This is a process where cells are biochemically marked by 
complement for removal by cellular immune components (Morgan BP., 2005). 
Inflammation: Certain complement fragments such as C5a are powerful 
anaphylatoxins and can induce a powerful pro inflammatory response (Basta 
et al., 2003, Gerard et al., 1994, Hugli et al., 1978) 
Innate-Adaptive bridging: The ability of complement to bind to antibody 
creates a significant link between the innate and adaptive immune systems 
(Morgan and Marchbank et al, 2005).                                                                                                                                
Immune clearance: The complement system plays a significant role in 
assisting the removal of immune complexes for eventual deposition in the 
spleen and liver (Bockow et al., 1981, Law et al., 1984). 
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1.3 The biosynthesis of complement Components 
 
Although the majority of proteins that constitute the complement system are 
synthesised by the liver, there are significant amounts produced by other cells 
such as macrophages, monocytes, Neutrophils and some epithelial cells. The 
main sites for the synthesis of each component are shown in table 1 below 
Component Primary Synthesis Site Secondary Synthesis Site 
C1q Macrophages Follicular dendritic cells, 
cells of monocyte 
macrophage lineage 
C1r Liver Epithelial, Endothelial and 
CNS Cells 
C1s Liver Monocytes, Epithelial, 
Endothelial and CNS Cells 
C2 Liver Monocyte Macrophage cell 
lineages, Fibroblasts 
C3 Liver Monocytes, Macrophages, 
Fibroblasts, T Cells, 
Astrocytes, Adipocytes. 
C4 Liver Monocytes, Macrophages, 
Mammary Glands, Lung, 
Spleen, Kidney, Brain and 
Testis 
C5 Liver Lung, Spleen, Monocytes, 
Macrophages and Foetal 
Intestine. 
C6 Liver Macrophage 
C7 Granulocytes, Liver No major secondaries 
C8 Liver Monocytes, Macrophages, 
Fibroblasts and Astrocytes 
C9 Liver Monocytes, Fibroblasts and 
Glial cells 
FACTOR B Liver Mononuclear Phagocytes 
and Fibroblasts 
FACTOR D Adipose Tissue Monocyte Macrophage cell 
lineages 
MBL Liver Kidney 
MASP1 Liver No major secondaries 
MASP2 Liver No major secondaries 
Table 1. The primary and secondary biosynthesis sites for complement components. Adapted 
from Morley and Walport, The Complement Facts book, Academic Press 2000.  
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Biosynthesis for all complement components is not always a steady, 
continuous process. Many components, the most notable being C3, are acute 
phase reactants and the synthesis of these components is strongly dependant 
on the local cellular environment such as the presence and concentration of 
cytokines such as IL-1, IL-6, IFNα or Lipopolysaccharide(LPS) (Purwar et al., 
2006 and Migita et al., 1990). Even at this point a further layer of complexity is 
added by individual cell type response where, for example C3 production by 
Neutrophils is actually down regulated by IL-1 (Botto et al., 1992). 
Furthermore, not all complement proteins are secreted rapidly, as 
demonstrated by Neutrophils which have been observed to store significant 
amounts of C7 (Hogasen et al., 1995). In the complement terminal pathway 
both C5 and C6 are relatively strong acute phase reactants compared to C7, 
and this can often lead to a molar deficit of C7 during an acute phase 
response (Lachmann et al., 1970). 
 
1.4. The Complement Activation Pathways 
 
There are three main pathways by which complement is activated, and these 
are the classical, alternative and mannose binding lectin pathways (Agostoni 
et al., 1992, Matsushita., 1996, Pangburn., 1983).  
The classical pathway typically requires an antibody-antigeninteraction for 
activation which then binds to C1q (Sim and Reid., 1991). The antibody 
required to activate the classical pathway is either IgG or IgM, as other 
immunoglobulin classes do not activate complement via C1q. The ability of 
IgG isotypes to activate complement via C1q in descending order of efficiency 
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from IgG1>IgG3>IgG2>>IgG4 which is a poor C1q activator of complement 
(Bindon et al., 1988). 
The C1 complex is formed when C1q binds to either IgM or IgG complexed 
with an antigen, or occasionally when C1q binds to a target cell surface (Sim 
and Reid., 1991). This leads to the activation of C1r and C1s, and two 
molecules each of these C1 subcomponents form another complex with the 
C1q complex creating macromolecular C1. It is the activation of C1 that leads 
to the cleaving of C4 into C4a and C4b. This then exposes a highly labile 
thioester bond within C4b, which under normal circumstances would be 
quickly hydrolysed (Law et al., 1997). In the presence of a suitable activating 
surface such as a microorganism or an immune complex C4b can form 
clusters near the activating C1 complex (Sim and Reid., 1991).  
This bound C4b can then act as an acceptor site for C2, which is then cleaved 
by the C1 complex or MASP. This leads to the formation of C4b2a, a C3 
convertase. 
The alternative pathway, unlike the classical pathway, is an antibody 
independent activation pathway that can be triggered by various substances 
such as zymosan, teichoic acid or lipopolysaccharide (Pangburn 1983). In 
aqueous solution, C3 continually undergoes a low level of hydrolysis to form 
C3(H2O) (Lachmann, P. J. and R. A. Thompson., 1970). This is capable of 
binding factor B, which acts as a substrate for factor D. This in turn forms 
C3(H2O)Bb, an unstable fluid phase C3 convertase capable of cleaving C3 to 
C3a and C3b. In the presence of a suitable activating surface, bound C3b will 
bind factor B. The C3bB can then undergo further cleavage by factor D to 
form the convertase C3bBb (Krishnan et al., 2009).  
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Given that the C3 convertase is formed by C3, this forms the basis of a 
continual and increasing amplification loop. The C3Bb complex then binds an 
additional C3b molecule which results in the formation of the C5 convertase 
C3bBbC3b (Gros et al., 2008). 
Although the mannose binding lectin (MBL) pathway can be activated by the 
hydrolysis of C3, the presence of activating surfaces is the mechanism most 
readily associated with the activation of this pathway (Epstein et al., 1996). 
These surfaces normally present molecules such as bacterial carbohydrates 
or lipopolysaccharides (LPS). These are capable of binding to MBL and 
initiating the pathway. 
The lectin pathway has many structural similarities to the classical pathway. 
The first classical pathway component C1q and mannose-binding lectin 
(MBL), share a similar „bunch of tulips‟ structure as shown in figure 2 below.  
 
Figure 2: a comparison of the structures of c1q and mbl 
 
In addition to this the MBL pathway shares C2, C3 and C4 with the classical 
pathway as the MBL-MASP complex can cleave C2 and C4.  
This pathway is activated by binding mannose-binding lectin to surface 
containing mannose, LPS or carbohydrates on the pathogen surface, which 
activates the MBL-associated serine proteases, MASP-1, and MASP-2. This 
then cleaves C4 into C4a and C4b and cleaves C2 into C2a and C2b (Garred 
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et al., 2003). Following this C4b and C2a then form the C3-convertase, as in 
the classical pathway.  
The activation of the classical, alternative or mannose binding lectin pathway 
involves a C3 convertase cleaving and activating C3, resulting in the 
formation of C3a and C3b which in turn results in an amplification of activation 
via further cleavage and activation. C3b has very significant opsonising 
capacity, which when bound to a cell surface leads to increased phagocytic 
killing by immune cells (Blom et al., 2009). 
The complement fragments C3a and C5a are powerful anaphylatoxins 
capable of inducing a strong pro-inflammatory response. The cleavage of C5 
results in the formation of C5a and C5b (Lambris et al., 1998). 
It is C5b that can initiate the complement terminal pathway and form the 
membrane attack complex, which consists of C5b, C6, C7, C8 and C9. 
The membrane attack complex is the final product of the terminal pathway 
cascade, and it forms a transmembrane channel capable of causing lysis of 
the target cell by membrane disruption (Podack., 1984a) as shown in figure 3. 
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Figure 3. An illustration of the membrane attack complex. The lytic pore is formed by the 
polymerisation of C9.  
 
The complement system can be extremely damaging to host tissues, and 
therefore its activation requires careful regulation. The complement system is 
regulated by complement control proteins, which are relatively abundant in 
serum compared to the complement proteins themselves (Morgan and 
Walport., 1991). Some complement control proteins such as MCP or DAF are 
present on the membranes of cells to prevent them from being subjected to 
autologous complement attack (Fosbrink et al., 2005). Specific terminal 
pathway regulators are clusterin and CD59, which inhibits C9 polymerisation 
during the formation of the membrane attack complex to avoid cell lysis 
(Morgan and Walport, 1991).  
The three activation pathways converge at the formation of a C3 convertase. 
Given that C3 forms a critical part of the complement cascade, it‟s structure 
and relative position of the thioester bond is shown in figure 4 below. It is this 
thioester bond which governs the functional activity of the C3 molecule, and 
therefore differs from the terminal pathway which is largely dependant on 
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conformational changes. The classical pathway results in the formation of 
C4b2a which can cleave C3 to C3a and C3b (Morgan and Gasque., 1997).  
 
Figure 4. A diagram representing the structure of C3. In addition to the position of the 
thioester bond, the N terminus (N), C terminus (c) and disulphide bonds (S) are also shown. 
 
In the presence of an activating surface, membrane bound C3b can bind to 
factor B. The factor B is cleaved by factor D for form Ba and Bb. The complex 
C3bBb remains intact whilst the Ba fragment is released. This forms a positive 
amplification loop as C3bBb cleaves more C3 to begin the loop again. It is the 
addition of a second C3b molecule that creates a C5 convertase (Pangburn et 
al., 1983). 
 
1.5 The Terminal Pathway 
 
The activation of either the classical, alternative or MBL pathway would 
normally lead to the formation of a C5 convertase and the activation of the 
terminal pathway with the release of C5b and the strong anaphylatoxin C5a. 
(Gerard and Gerard., 1994) The chemistry of the terminal pathway differs 
from that of the C3 family of proteins. Whereas, for example, C3 and C4 have 
activity mediated by an internal thioester bond, C5 does not have such a bond 
and activity is dependant on molecular conformational changes (Gros et al., 
2008). The terminal pathway as a whole requires conformational changes 
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resulting from binding interactions to work. Upon interaction of C3b in the 
convertase an acceptor site for C6 is exposed. 
The binding of C5b to C6 forms C5b6 which in turn forms a complex capable 
of binding C7 (DiScipio et al., 1988). A further conformation change on the C7 
part of the C5b67 complex allows binding to the target cell membrane (Mold C 
et al., 1998). The terminal pathway cascade continues when C8 binds to the 
C5b67 complex using the C8β part of the C8 molecule. A further 
conformational change allows the C8α part of C8 to bind to the cell membrane 
thus increasing the stability of the complex at the cell surface. The membrane 
attack complex (MAC) is then formed when C9 binds to the C5b678 complex 
and then C9 polymerises (Gros et al., 2008). 
The binding of C7 to C5b6 allows C5b6 to be released from C3b. The 
hydrophobic portion of C7 that binds to the cell membrane allows the complex 
to localise once again to the target cell surface (Mold et al., 1998). The time 
between the release of C5b6 from C3b and binding of C7 to the target cell 
membrane is small but between these two events the complex is not 
physically bound to a cell surface. Therefore, between the release from the 
C3b complex and C7 binding event it is possible for the MAC to localise to a 
nearby cell surface and cause damage by a process known as bystander lysis 
(Koch-Brandt et al., 1996).  
Upon the formation of the MAC on the cell surface, it is entirely possible that 
lysis will occur as a result of membrane disruption. It is also possible that a 
number of signalling pathways within the cell will be activated and a pro 
inflammatory response induced. 
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Several other non classical effects of the membrane attack complex have 
been reported. In some cases the membrane attack complex can cause cell 
proliferation or activation. It have also been noted that MAC deposition can 
induce resistance to further complement attacks, and that it can also induce or 
protect against apoptosis (Cole and  Morgan, 2003). 
The complement terminal pathway genes are located on chromosomes 1, 5 
and 9 (Campbell et al., 1988) as shown in figure 5   
 
Figure 5. The location of terminal pathway genes and the Regulators of Complement 
Activation. Figure adapted from www.pubmed.com. 
 
Complement C5 
 
C5 biosynthesis occurs as a single chain precursor of 1676 amino acids which 
includes an 18 amino acid leader sequence. The precursor contains both the 
C5 α and β chains linked by an arginine rich linker sequence (Ooi and Colten, 
1979). The leader and linker sequences are processed during secretion, at 
which point the mature C5 molecule adopts a two chain structure linked 
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together by disulphide bonds. The molecular weight of C5 is approximately 
190kDa, and it is expressed primarily in the liver, although other sties such as 
the lung, spleen and monocytes are also important. (Kohler and Müller-
Eberhard., 1967) The genomic location for C5 is 9q33 as shown in figure 5. 
 
 
Figure 6. Complement C5 protein precursor. The arginine rich linker sequence is represented 
at the centre of the molecule 
 
Although deficiency of C5 is rare compared to other terminal pathway 
components, a number of defects have been reported as shown on Table 2 
below 
Gene Mutation Consequence Location 
C5 84C>T Q19X Exon 1 
C5 892C>T Q298X Exon 9 
C5 1115A>G Splicing Defect Exon 10 
C5 1183_1184CAG>CTCT Splicing Defect Exon 15 
C5 2536T>C Missense Exon 20 
C5 4521C>T PTC Exon 36 
C5 4884CCC>GC Missense Exon 40 
  
Table 2. Mutation currently reported in the C5 gene 
 
Complement C6 
 
C6 is also synthesised as a single chain polypeptide of 934 amino acids. It 
has a leader peptide, which is 21 amino acids long (Hobart et al., 1995). The 
mature C6 molecule has a molecular weight of around 100kDa, and is 
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synthesised primarily in the liver. C6 is an acute phase reactant. The C6 gene 
is located at 5p12, in close proximity to C7 and C9 (Campbell et al., 1988). 
 
 
Figure 7. Complement C6 protein precursor. Figure abbreviations are listed in the main 
abbreviations section above. 
 
The C6 gene has a number of defects associated with it, as shown in table 3 
below 
Gene Mutation Consequence Location 
C6 234delC Termination Codon Exon 2 
C6 446+3A>C Splicing Defect Intron 4 
C6 821delA Termination Codon Exon 7 
C6 822delG Termination Codon Exon 7 
C6 1138delC Termination Codon Exon 8 
C6 1542T>A Termination Codon Exon 10 
C6 1879delG Termination Codon Exon 13 
  
Table 3. Mutations currently reported in the C6 gene 
 
 
Complement C7 
 
Complement component C7 is synthesised as a single polypeptide of 843 
amino acids which includes a 22 amino acid leader sequence (Hobart et al., 
1995). It is a relatively weak acute phase reactant which can lead to a molar 
imbalance with C5 and C6 during an acute phase response (Lachmann and 
Thompson., 1970). C7 is synthesised primarily by granulocytes, with no 
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significant secondary synthesis site as yet being identified. The C7 gene 
approximately 80kB and is located at genomic position 5p12-14 close to C6 in 
a 3‟ to 3‟ orientation (DiScipio et al., 1988). 
 
 
Figure 8. Complement C7 protein precursor. Figure abbreviations are listed in the main 
abbreviations section above. 
 
The defects associated with complement C7 are shown in table 4 below. 
Gene Mutation Consequence Location 
C7 189T>G C41W Exon 3 
C7 1135G>C G357R Exon 9 
C7 1561C>A R499S Exon 11 
C7 1741-3delT F569fs14X Exon 12 
C7 1924delAG S620fs10X Exon 14 
C7 2107C>T Q681X Exon 15 
C7 4009+2T>C Splicing Defect Intron 16 
  
Table 4. Mutations currently reported in the C7 gene 
 
 
Complement C8 
 
C8 is unique in the terminal pathway insofar as it is synthesised from three 
separate polypeptides, C8α, C8β and C8γ (Rosa et al., 2004). 
C8α and C8 γ form a disulphide linked heterodimer, with C8β being linked non 
covalently to form the mature C8 molecule. In a solution at high ionic strength 
the C8α-γ complex can be isolated and purified.  Each sub unit of C8 is 
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(Michelotti et al., 1995) encoded by a different gene, with the lipocalin C8γ 
gene being located on a different chromosome (Kaufman et al., 1994). Of all 
the complement proteins, C8γ is the only lipocalin. These molecules have a 
roughly hollow hemispherical shape (from the Latin calyx meaning cup) and in 
the case of C8γ the ligand for the central hollow space is yet to be identified. 
The defects associated with each of the α, β and γ subunits of complement 
C8 are shown in figure 9 below 
 
Figure 9. Complement C8 protein precursors 
 
Gene Mutation Consequence Location 
C8A 952-12G>A Termination Codon Intron 6 
C8A 952-15G>A Termination Codon Intron 6 
C8A 267+1T>C Splicing Defect Intron 2 
C8A 1407C>T Termination Codon Exon 10 
C8B 271C>T G91X Exon 3 
C8B 336delC T112Tfs23X Exon 3 
C8B 361C>T R121X Exon 3 
C8B 605delC P202Rfs5X Exon 5 
C8B 820C>T R274X Exon 6 
C8B 1047_1053dupGGCTGTG L350Gfs8X Exon 7 
C8B 1282C>T R428X Exon 9 
C8B 1309C>T Termination Codon Exon 9 
C8G None None None 
  
Table 5 Mutations currently reported in the C8 genes 
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Complement C9  
 
It is the ability of C9 to polymerise and form tube like structures that governs 
the lytic function of the membrane attack complex as shown in figure 2. C9 is 
synthesised as a single chain polypeptide that is located within 3Mb of the C6 
and C7 genes. At 90Kb long, C9 shares considerable homology with a protein 
expressed on NK cells often referred to as C9 related protein (Müller-
Eberhard HJ et al., 1987). 
 
 
Figure 10. Complement C9 protein precursor. Figure abbreviations are listed in the main 
abbreviations section above. 
 
The C9 protein has fewer reported defect than other terminal pathway 
proteins, which are listed in table 6 below  
Gene Mutation Consequence Location 
C9 166C>A C53X Exon 2 
C9 350C>T R115X Exon 4 
C9 464C>T R153X Exon 4 
  
Table 6. Mutations currently reported in the C9 gene 
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1.6 Complement Deficiency and Disease 
 
Historically, complement deficiency has been considered when a patient has 
had a number of recurrent infections or an infection has taken abnormally long 
to clear (Colten and Rosen., 1992). 
The complexity of the complement system is such that it plays a significant 
role in the majority of diseases, and therefore specific symptoms are 
sometimes difficult to attribute to complement deficiency (Lambris et al., 
1998).  
Deficiencies of components in the classical pathway can lead to an increased 
susceptibility to bacterial infections (Haeney et al., 1998), in particular 
polysaccharide encapsulated bacteria (Colten and Rosen., 1992)  A 
deficiency of C1 inhibitor has been shown to cause hereditary angioaedema 
(HAE) (Agostoni and Cicardi., 1992). In addition to this, deficiencies of the 
classical pathway have been strongly linked to a disease which is similar to 
systemic lupus erythematosus (Manoharan and Madaio., 2010).  
Mannose-binding lectin deficiencies are thought to be amongst the most 
common complement deficiencies, in some populations a prevalence as high 
as 30% of the population are reported as being deficient (Garred et al., 2003) 
It must be pointed out that in addition to complete deficiency the range of MBL 
present in human serum can vary between 5-10μg/L and 10,000μg/L and so 
the function point at which MBL deficiency can be defined may not be clear. In 
addition to this four variant allotypes of MBL exist and are relatively abundant 
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(Garred et al., 2003). A reduced MBL concentration has been linked to 
increased susceptibility to bacterial infections. 
Alternative pathway deficiencies are also associated with an increased 
susceptibility to bacterial infections (Figueroa et al., 1991). 
Specific complement component deficiencies are associated with particular 
diseases. Factor H deficiency is associated with a disease called 
membranoproliferative glomerulonephritis and atypical haemolytic ureamic 
syndrome(aHUS), and CD59 deficiency is associated with paroxysmal 
nocturnal hemoglobinuria (Morgan and Walport., 1991).  
Complement terminal pathway deficiency leads to an increased susceptibility 
to Neisserial infections and recurrent meningococcal disease (MD). Although 
terminal pathway deficient individuals do experience an increased risk of 
disseminated gonorrhoea, it is the risk of recurrent Neisseria meningitidis 
infections that poses the most severe health risk (Morgan and Orren., 1998).  
Complement sufficient individuals do not normally experience multiple 
Neisseria meningitidis infections, and although infection poses a risk to all age 
groups, a comparison of the age of first infection in both complement sufficient 
and deficient patients suggests that there is no difference between the age 
distributions of complement sufficient and deficient groups, implying that 
complement terminal pathway deficient individuals are a suitable research 
cohort for the study of Neisseria  infections in humans (www.neisseria.org).  
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1.7 The molecular heterogeneity of Complement Components 
 
1.7.1 Protein investigations of Terminal Complement Pathway Deficiency 
 
A protein based study of each terminal complement pathway component 
should determine the nature of the deficiency. It is advisable to use a 
polyclonal antibody to the complement component of interest as it may be 
possible for an abnormal form of the protein to be missed by a monoclonal 
antibody (Lipman et al., 2005). The presence of an abnormal form of protein 
may also be seen if the patient serum sample is separated electrophoretically 
prior to immunoblotting. Normally a western blot can be completed within a 
day, producing a result strongly indicating terminal pathway abnormality 
 
1.7.2 Genomic investigations of Complement Terminal Pathway 
deficiency 
 
Although determining the molecular basis of the deficiency can often be 
achieved by the genomic PCR amplification of the sequence around known 
defects, a wider study may be necessary. It would comprise all exons and 
their surrounding intronic regions, the promoter region and both the 5‟ and 3‟ 
untranslated regions. The development of a method for generating these 
genomic PCR fragments was recommended. Occasionally, a compound 
defect may be present, such as a large deletion or insertion, which can be 
22 
 
obscured by the amplification of DNA from the unaffected allele (Ball et al., 
2005). In addition to this there is the possibility that epigenetic modifications, 
such as changes in methylation patterns, may affect the production of 
complement components (Chen et al., 2007). 
 
1.7.3 RNA investigations of Complement Terminal Pathway deficiency 
 
Performing a study of mRNA may not always be a straightforward matter. In 
addition to the standard problems of producing cDNA and avoiding mRNA 
degradation, most terminal pathway components are synthesised in 
hepatocytes and these are not readily available from patients. Although 
biosynthesis does occur in many blood cell types, identifying the correct cell 
type for a given assay can be essential when the abundance of a particular 
transcript in a deficient individual may be of critical. 
Even at this stage, the identification of a defect may not be clear. Some 
mutations further within an intronic region can have pathological 
consequences (Blyth et al., 2010), and some epigenetic modification can 
affect gene expression. On occasion, an observed mutation may not be 
strongly associated with splicing or result in a significantly different amino acid 
change (Rameix-Welti., 2007).  
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1.8 The aims of this study 
 
The purpose of this study is to develop methods of investigating complement 
terminal pathway deficiency and to apply these method to patients suspected 
of having complement terminal pathway deficiency.  
 
1.8.1 The investigation of C5 defects in a case of C5 deficiency in South 
Africa 
 
Cases of C5 deficiency are rare in Western countries, with less than 100 
being reported to date. In this section studies focus on a young Xhosan 
woman who was diagnosed with C5 deficiency after two attacks of 
Meningococcal disease (MD). I have collaborated in studies conducted on 
proteins, genomic DNA and cDNA samples.  
In addition to this work was undertaken to ascertain the best source of patient 
sample material. This focused on the isolation or enrichment of specific cell 
types in order to maximise the potential to observe low levels of C5. 
 
 
1.8.2 The characterisation of a large C7 genomic defect in the Irish  
Population 
 
The identity of the C7 molecular defect in four Irish families was investigated 
(Thomas et al., 2012). Previous studies had showed a large genomic deletion, 
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and in this study the molecular identity of the deletion breakpoints has been 
determined and a novel 8bp insert identified. 
 
 
1.10.3 The identification of C8β genomic defects in UK patients 
 
A number of patients resident in the UK have presented with recurrent 
Meningococcal disease, and diagnosed with C8β deficiency (Arnold et al., 
2009). In this study the molecular bases of these defects have been 
determined and the results suggest the frequency with which specific defects 
occur may be higher than expected. 
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Chapter 2 
Experimental Methods 
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2.1 Isolation of nucleated cells from a sample of whole blood  
 
The removal of erythrocytes and subsequent isolation of nucleated cells is a 
useful technique in the production of genomic DNA, RNA or the EBV 
immortalisation of B cells. Although serum does contain a little genomic DNA 
from cells that have undergone lysis, the highest concentration of genomic 
DNA within the blood exists within viable nucleated cells (Miller et al., 1988). 
Producing RNA suitable for reverse transcription requires a rigorous process; 
primarily due to the ease with which RNA can be degraded.  
The method detailed here was designed to allow a lapse of about 12 hours 
between sample collection, and the isolation of nucleated cells. This enabled 
the protocol to be used when a blood sample needed to be transported back 
to the laboratory.  
 
Method 
 
Samples of about 15 ml of blood were collected into tubes containing heparin, 
and when necessary they were placed in a suitable container for 
transportation.  
DNA isolation for a single sample was performed by taking 5 ml of the blood 
sample and gently mixing it with 5 ml of sterile PBS. The blood mixture was 
then overlaid very carefully onto 10 ml of Lymphoprep. It was this step that 
determined the quality and yield of nucleated cells. 
The sample was centrifuged for 30 minutes at 900g, using low braking 
conditions and at room temperature. The serum lymphoprep interface 
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contains the buffy coat with nucleated cells as show below. This layer should 
be visibly cloudy if nucleated cells are present. 
 
 
Figure 11. The visible layers produced after a lymphoprep gradient separation are 
represented. In practice the buffy coat is observed as a thin white opaque band. 
 
The buffy coat was harvested into a sterile 15ml falcon tube using a sterile 
1ml tip. An excess of sterile PBS was added to the tube to wash the nucleated 
cell sample, which was centrifuged for 10 minutes at 1300g and at 4°C. This 
wash step was then repeated another two times. The cells were resuspended 
in 1 ml of sterile PBS.  
In order to assess cells isolated from the buffy coat, a haemocytometer was 
used. 
The haemocytometer was loaded with a mixture of 10μL of cells and 10μL of 
trypan blue. The total cells were counted as well as the viable (non blue) cells. 
The cell density per ml is given as count x (2x104) and can be calculated for 
both total and viable cells. The two measurements were taken to assess the 
possibility of RNA degradation due to cell lysis. 
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The optimum number of cells for RNA isolation is 106 cells. Using the cell 
density counts above, the volume of sample necessary to provide 106 cells 
was calculated.  
2.2 The isolation of Neutrophils from whole blood 
 
Neutrophils are the most common cell type in blood circulation. They are short 
lived and play a significant role in complement biology such as responding to 
the presence of C5a (Ember et al., 1998), or in the synthesis of complement 
component C7 (Hogasen et al., 1995). Neutrophils can synthesis and store 
large amounts of C7, and it is for this reason that neutrophil activation should 
be avoided.  
Method 
When isolating neutrophils all steps were completed at 4°C and excessive 
vibration was avoided in order to limit activation. In addition to this, glass 
tubes were not used as the cells become adherent to the glass surface and 
cannot be recovered. 
The method separated neutrophils in three steps: 
The first step: Dextran sedimentation. This step removed most of the 
erythrocytes, which sediment at the bottom of the tube.  The leukocytes and 
lymphocytes remained suspended in solution. 
The second step: Hypotonic lysis.  This step removed any remaining 
erythrocytes and platelets. The leukocytes and lymphocytes did not undergo 
lysis. 
The third step: Lymphoprep sedimentation. It was during this step that 
mononuclear cells were separated from neutrophils. The neutrophils sank to 
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the bottom of the Lymphoprep, and mononuclear cells remained at the 
interface. It is worth noting that the mononuclear cells can also be harvested 
during this procedure. 
Each sample was processed by firstly taking 20ml of whole blood which was 
then carefully poured down the inside of a 50ml conical tube containing 4 ml 
ACD buffer. The tube was gently inverted several times to mix the contents. 
Then, 12 ml of 6% Dextran solution was pipetted into the ACD/blood mixture 
and was then gently inverted 20 times to ensure the mixture is homogenised. 
The mixture was then pipetted into 4 x 15ml tubes, which equated to around 
10ml per tube.  
The tubes then stood at room temperature until separation occurred, which 
normally takes around 1 hour. The separation time can be reduced by 
centrifuging the tubes at 20g for 20 minutes at room temperature. 
The supernatant was then pipetted into a 50 ml falcon tube, and centrifuged at 
1150 rpm for 12 minutes at 4°C using low braking conditions. 
Next, the pellet was resuspended in 12 ml of the ice-cold dH2O. The mixture 
was homogenised by repeated pipetting. Hypotonic lysis was carried out by 
adding 4 ml of cold 0.6 M KCl and mixing several times. The solution was 
diluted to 50 ml with cold sterile PBS. The tubes were then centrifuged at 
1300 rpm for 6 minutes at 4°C using a high braking conditions. 
The hypotonic lysis stage was performed up to three times to ensure 
complete removal of erythrocytes. Each stage can result is some cell loss, so 
the balance between cell yield and erythrocyte contamination was judged 
according to experimental requirements. 
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The supernatant was then discarded, and the pellet resuspended in 2.5 ml of 
cold sterile PBS.  
Very carefully, the cell suspension was layered over 3 ml of Lymphoprep in a 
15 ml tube. The tubes were centrifuged at 1500 rpm for 30 minutes at 4°C 
using high braking conditions. The supernatant was aspirated and the pellet 
resuspended. Cells remained viable suspended in HBSS for about 4 hours at 
4C, or two hours at room temperature. Nevertheless, the cells were always 
used as quickly as possible. 
 
2.3 The isolation of nucleic acids from blood and serum using Trizol 
phase separation reagent 
 
The isolation of nucleic acids does not necessarily rely on the availability of 
whole blood. Although RNA stability is effectively negligible in dried blood and 
stored serum samples, it is possible to isolate genomic DNA from such 
sources. Although they do not contain nucleated cells and therefore are not 
preferred as high yield sources, they do contain DNA from cells that have 
undergone lysis. 
The process of isolating nucleic acid depends upon the initial starting material, 
although in each case there was a method convergence at the phase 
separation level. 
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Whole Blood 
 
The cells were first harvested using Lymphoprep as described above, and 106 
cells were subjected to lysis using 1ml of Trizol reagent. 
The lysate was then incubated at room temperature for 5 minutes to allow 
complete dissociation of nucleoprotein complexes. Then 200μL of chloroform 
was added to the tube which is then shaken vigorously for 15 seconds. The 
mixture was then incubated at room temperature for 5 minutes. The tube was 
then centrifuged at 12,000g for 15 minutes at 4°C. Upon removal from the 
centrifuge the contents had separated into an aqueous and organic phase. 
The upper phase was the aqueous phase and contained the RNA. The lower 
pink organic phase contained DNA and protein.  
To isolate RNA, the colourless aqueous phase was then transferred to a clean 
tube and 500μL of isopropanol was added. The sample was centrifuged at 
12000g for 30 minutes at 4°C. The supernatant was discarded and pellet was 
washed twice with 75% ethanol, after being centrifuged at 12000g for 30 
minutes at 4°C between washes. The pellet was air dried and resuspended in 
10mM EDTA 10mM Tris pH 8.0. Care was taken to avoid over drying the 
pellet as this significantly impeded resuspension. 
When necessary the pink organic phase was used to isolate DNA, with the 
highest DNA concentration being near the interphase.  
The organic phase was transferred to a clean tube and after complete 
removal of the aqueous phase the DNA was precipitated by the addition of 
300μL of 100% ethanol. The sample was mixed by inversion and then 
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incubated at 15 to 30°C for 5 minutes. The DNA was precipitated by 
centrifuging at 2,000g for 5 minutes at 4°C. 
The DNA pellet was then washed twice in a solution containing 0.1 M sodium 
citrate in 10% Ethanol solution. At each wash, the DNA pellet was incubated 
in the washing solution for 30 minutes at room temperature, and centrifuges at 
2,000g for 5 minutes at 4°C. After these two wash steps, the DNA pellet was 
suspended in 2ml in 75% ethanol, and then incubated for 20 minutes at room 
temperature. The pellet was air dried and dissolved in 10mM EDTA 10mM 
Tris pH 8.0. 
 
Dried Blood 
 
The presentation of a dried blood sample, such as a blood spot on filter paper, 
can be used as a source of genomic DNA. The material containing the dried 
blood was excised with a clean sharp scalpel and incubated in 500μL of Trizol 
overnight with constant mechanical agitation on laboratory rollers.  
The volume of Trizol reagent used for extraction was half of that used for 
extraction from whole blood, and therefore all downstream reagent volumes 
were similarly reduced by a half.  
Similarly to whole blood, chloroform is added and DNA extracted from the 
organic phase as described above.  
Dried blood was not a suitable source material for RNA extraction 
(unpublished result). 
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Serum 
 
On occasion a serum sample was used in place of a white blood cell pellet as 
described above provided the serum volume is below 50μL. In cases where 
the sample volume used was more than 50μL, it was possible to centrifuge 
the sample under vacuum until the sample volume is below 50μL. All reagents 
and volumes used are then as per the whole blood method. 
In common with dried blood samples, serum is not a suitable source material 
for RNA isolation. 
 
2.4 The assessment of RNA quality 
 
The risk of RNA degrading during the RNA isolation protocol or during storage 
means that RNA quality should be assessed prior to use. This was done 
either by measuring the RNA sample‟s UV absorbance or by RNA gel 
electrophoresis. 
 
Method 
 
UV Absorbance: The equipment routinely used to measure UV absorbance 
was a nanodrop ND1000 UV spectrophotometer. A 2μL sample of RNA 
elution buffer was first used to generate a blank reference for the nanodrop 
spectrophotometer. A 2μL sample of RNA was placed on the nanodrop 
measuring pedestal. The reader arm is then lowered and a UV absorbance 
measurement was taken. A UV absorbance measurement was taken for all 
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RNA isolations. The nanodrop generates a wavelength absorbance graph 
which was used to assess degradation, contamination or storage degradation 
by comparing graphs before and after storage. 
 
RNA gel electrophoresis: This method was optimised for RNA fragments of 
between 2kB and 6kB. The percentage of agarose can be varied for RNA 
outside of this range.  
It was possible to resolve the 18S rRNA and 28S rRNA bands in the RNA 
sample in order to assess potential degradation of the sample. In a good 
sample the 28S band has an intensity of about twice that of the 18S band.  
A suitable volume of around 2L of l0x FA gel buffer was prepared to pour the 
gel. In addition to this around 2L of FA gel running buffer was prepared to fill 
the RNA electrophoresis tank.  
Firstly, 200ml of agarose gel was made by mixing 2.2g agarose, 20ml, l0x FA 
gel buffer and then RNase-Free water was added to 200 ml. 
The mixture was heated in a microwave, with the vessel swirled occasionally 
until the agarose was completely dissolved. 
The agarose was cooled to 65°C in a water bath, and then 3.6 ml of 37% 
(12.3 M) formaldehyde and 2μL of ethidium bromide solution were added. 
The gel was cast in a fume cabinet. It was ensured that the gel was 
completely set before removing the gel comb. The gel was placed in the 
electrophoresis tank which was then filled with FA gel running buffer. The gel 
was equilibrated in FA gel running buffer for at least 30 minutes. 
In an RNase free sterile micro centrifuge tube, 5μL of 5x RNA loading buffer 
was added to 20μL of RNA sample, and denatured by incubating at 65oC for 4 
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minutes. Immediately after this incubation the sample was placed on ice for 
10 minutes. 
The RNA samples were loaded onto the gel and electrophoresed at a low 
voltage until the dye had migrated about 2/3 of the way across the gel. The 
gel was then visualized and photographed under UV light. 
 
 
2.5 The reverse transcription of mRNA to produce cDNA  
 
Although a number of RNA dependant DNA polymerase enzymes were 
commercially available, only Thermoscript and Superscript III were used. 
These products were supplied by Invitrogen (Paisley, UK). Thermoscript is a 
high temperature avian derived enzyme and Superscript III is a proprietary 
mutant of reverse transcriptase that is active at 60°C and has a half-life of 220 
minutes. 
Although it is possible to use gene specific primers to initiate the cDNA first 
strand synthesis reaction, the possibility of having causative mutations under 
gene specific primer annealing sites precludes this option. Therefore, two 
options were considered for priming the first strand synthesis reaction 
Oligo(dT): a more specific priming method, was used to hybridize to 3‟ poly(A) 
tails, which are found in the vast majority of eukaryotic mRNA. Given that 
mRNA constitutes between 1 and 3% of the total RNA, the amount and 
complexity of cDNA produced is considerably less than with random 
hexamers. The cDNA synthesis performed in these experiments were 
performed with Oligo (dT)12-18. Although Oligo (dT)20 has been reported to give 
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more consistent results at higher cDNA synthesis temperatures (Veres et al., 
1987), it has been reported that such reaction can be less robust (Noonan 
and Roninson., 1988). 
Random Hexamers: Random hexamers are the most non-specific priming 
method (Breslauer et al., 1986), and are typically used when it is difficult to 
copy the full length mRNA. Using this method, all RNAs and not just mRNA‟s 
in a population are templates for first-strand cDNA synthesis. It is the PCR 
primers that confer specificity during the PCR amplification stage.  
The length of cDNA produced was dependant on the concentration of random 
hexamers used in the first stage synthesis reaction. In generally, the lower the 
hexamer concentration the greater the maximum length of the cDNA 
produced. In order to maximize the size of cDNA produced, one should 
determine the ratio of random hexamers to RNA experimentally for each 
cDNA synthesis reaction.  
Two guidelines for the generation of cDNA that may be beneficial are firstly, if 
generating cDNA at temperatures above 50°C using oligo(dT)12-18, the amount 
of Superscript III may be raised to 2μL to increase yield (Houts et al., 1979). 
Secondly, the addition of an RNase inhibitor for low levels of template RNA is 
strongly recommended (Scheele et al., 1979). Using a recombinant RNase 
inhibitor with higher starting concentrations of RNA template did not produce 
any deleterious effects. It may therefore be used routinely during first strand 
synthesis. 
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Method 
 
All reactions were set up for a 20μL reaction volume, utilising 100 to 500ng of 
total RNA. An initial mixture of 1μL of either of oligo(dT)12-18  or 50ng of 
random hexamers, RNA template, 1μL 10mM dNTP Mix and sterile dH2O to a 
volume of 13μL was produced. This mixture was heated to 65°C for 5 minutes 
and then incubated on ice for 1 minute. After being centrifuged briefly to 
collect the tube contents 4μL 5X First-Strand Buffer, 1μL 0.1M DTT, 1μL 
RNase inhibitor and 1μL of Superscript III were added. If random hexamers 
were used, then an initial incubation at 25oC for 5 minutes was performed. 
The first incubation was conducted at 50°C for 45 minutes to facilitate the 
reverse transcription, unless dealing with a difficult template where the 
incubation can be increased to 55°C. The reaction was heat inactivated by 
heating the cDNA to 70°C for 15 minutes. 
The cDNA was then used as a template for amplification in PCR. However, 
amplification of the PCR target required the removal of RNA complementary 
to the cDNA, which was achieved by adding 1μL of RNase H and incubating 
the mixture at 37°C for 20 minutes. Wherever possible, primers were 
designed to overlap exon boundaries. 
 
2.6 Polymerase Chain Reaction 
 
This technique allows the amplification of large amounts of specific DNA from 
small amounts of initial template. The reaction undergoes a phase during 
which the amount of template doubles with each PCR cycle, assuming 100% 
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efficiency. As primers and dNTPs are consumed in the reaction, the increase 
in PCR product will slow down. Given that PCR product serves as a template 
for the reaction in the next PCR cycle and that typically 25 to 35 cycles of 
PCR can be performed, the amount of product capable of being produced is 
therefore large. 
 
Method 
 
A PCR mixture was produced in accordance with the components and 
amounts listed in Table 7 for a 50μL reaction. The PCR mix must be made in 
a clean DNase, RNase and pyrogen free tube certified for PCR. The 
components were thawed on ice and kept on ice throughout pipetting. The 
enzyme used for standard PCR amplification was Promega GoTaq 
(Southampton, UK) unless otherwise stated. 
 
Component Volume (μL) Final Concentration 
DNA template 0.5 Less than 250ng* 
5x Buffer 10 1x 
MgCl2 In buffer 1.5mM 
Primer (sense) 50pM μL-1 0.25 12.5pM 
Primer (sense) 50pM μL-1 0.25 12.5pM 
10mM dNTPs 1 0.2mM 
GoTaq DNA Polymerase 0.25μL 1.25 units 
dH2O To 50μL N/A 
Table 7. The individual components for a PCR reaction mixture. (*) The amount of DNA can 
vary significantly, although excessive quantities such as 250ng should be avoided. 
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Also additional magnesium chloride was used where specified. It was also 
possible to use a buffer without magnesium and add back magnesium in 
order to achieve concentrations below 1.5mM. 
Thermal cycling normally consists of four steps. The first step is a single 
denaturation step of between 1 and 5 minutes. Then the following three steps 
are cycled, a denaturation step of 30-60 seconds, an annealing step of around 
30 seconds and an extension step of around 60 seconds per kilobase. 
Once produced, the PCR reaction mixture was subjected immediately to 
thermal cycling. The number of thermal cycles used can vary but these are 
normally between 25 and 35 cycles. All thermal cycling was performed on an 
MJ Research DYAD PCR machine. MJ Research is now part of Bio-Rad 
Laboratories (Hemel Hempstead, UK). This machine was equipped with a 
heated lid, and therefore mineral oil was not required. The following thermal 
cycling profile is typical. 
 
Initial Denaturing:  95°C   120 seconds 
Denaturing:   95°C   30 seconds 
Annealing:   55-65°C  30 seconds 
Extension:   72°C   60 seconds per kilobase 
Number of DAE cycles: 35°C   35 
Final Extension:  72°C   600 seconds 
 
On completion of thermal cycling the product was kept at 4°C, which is 
normally included in the PCR program. The annealing temperature used was 
dependant on the characteristics of the primer pair used. 
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2.7 Optimising Polymerase Chain Reactions 
 
The use of polymerase chain reaction (PCR) is routine in both research and 
clinical settings. Extensive guidelines for the design of primers, purification of 
DNA template and choice of enzyme exist (Dieffenbach and Dveksler., 1995). 
It was noted, however, that the empirical refinement of specific PCR is often 
required. Although some elements are routinely optimised, it was found 
beneficial to consider optimising all regent components and all steps in the 
thermal cycling conditions for difficult reactions. 
 
Method 
 
The annealing step: This was optimised by running a PCR reaction with the 
annealing step set to a thermal gradient. This took the form of twelve identical 
reaction mixtures being subjected to nearly identical thermal cycling 
conditions in which the only variation was that each successive tube 
experiences a higher annealing temperature. An example of this would be 
where the first tube was subjected to an annealing temperature of 50°C and 
the twelfth tube was subjected to an annealing temperature of 60°C with the 
intervening tubes being subjected to incremental temperature increases 
defined by the manufacturer of the PCR thermal gradient cycling machine. 
Post PCR samples were electrophoresed on an agarose gel and imaged 
under ultra violet light to ascertain the optimum annealing temperature for the 
specified PCR reaction. Generally, the higher the PCR annealing 
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temperature, then the higher the reaction specificity (Dieffenbach and 
Dveksler., 1995). 
Magnesium concentration: Magnesium ions are a critical cofactor for the 
function of thermostable DNA dependant DNA polymerases (Dieffenbach and 
Dveksler., 1995). Although other factors influence successful PCR reactions, 
the concentration of magnesium ions and annealing temperature form the 
basis of most optimisations. A range of magnesium concentrations between 
0.5 and 4mM in increments of 0.5mM were explored. As the magnesium 
concentration increased, the efficiency of magnesium as a PCR cofactor 
increases to a maximum. Beyond this point the primers begin to anneal in a 
non specific manner, thus generating multiple non-specific products and 
eventually no product at all. The magnesium concentration and annealing 
temperature may be optimised in a single round of experiments using a 96 
well PCR plate as shown in figure 12 below 
 
 Figure 12: A schematic diagram of an initial PCR optimisation plate. This enables the 
optimal annealing temperature and magnesium chloride concentration to be quickly identified. 
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Buffer Optimisation: Commercially available polymerases are supplied with 
both a specific buffer and instructions relating to buffer concentration. It is 
possible to change the buffer concentration from between 0.5 and 2 times that 
recommended by the manufacturer. As the concentration of buffer increased 
the specificity of the PCR reaction also increased (Dieffenbach and Dveksler., 
1995). 
The type of buffer may be changed depending on the nature of the PCR to be 
attempted. An NH4 based buffer tends to result in a more robust reaction, 
whilst a KCl based buffer will result in a reaction with higher specificity. 
Deoxynucleosides (dNTPs): Most manufacturer protocols will recommend, for 
example, a dNTP concentration of 0.2mM for each component when 
performing a PCR with 1.5mM MgCl2.  Although this can be optimised there is 
one critical aspect that must be observed. In order for the reaction to succeed 
free magnesium ions are required, and at the point where the dNTP to 
magnesium concentration breaks parity the reaction becomes rapidly 
inhibited. Although the magnesium concentration can be increased to counter 
this, the concentrations listed above should yield sufficient product for most 
downstream applications. 
Also dNTPs are prone to degrade with excessive freeze thawing, and should 
therefore be stored in small aliquots prior to use. 
Primer Design and Concentration: Although many PCR primer design 
programs are available free of charge via the internet such as primer3 
(http://primer3.sourceforge.net/), there are some aspects of the design 
process that benefit from careful selection (Innis et al., 1999). The primers 
should not contain sequences that readily self anneal or dimerise, and they 
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should have a GC content of between 40-60% and similar melting (Tm) 
temperatures (Innis et al., 1999) . They should also be of similar length, with 
around 18 to 25 bases being typical. Modern sequence analysis has allowed 
two additions to the design process. Firstly, the target template can be 
scanned for regions of repetitive DNA and this should then be avoided 
(Cordaux and Batzer., 2009). Secondly, the primers themselves can be 
subjected to a BLAST (Basic Local Alignment Search Tool) to ensure that the 
primer sequence is complimentary to the target annealing site only (Altschul 
et al., 1990). 
The required primer concentration should be determined empirically. The 
presence of strong primer dimer bands when imaged under UV light can 
sometimes be indicative of excessive primer concentration.  
Polymerase: When choosing the polymerase for a reaction, the end 
requirements of the reaction dictate which polymerase to use. A simple PCR 
based screen requires a robust reaction where fidelity is less important than 
robustness, so an enzyme derived from Thermus Aquaticus (Taq) may be 
most appropriate. In a reaction where the PCR product is to be cloned a 
higher fidelity enzyme derived from an organism such as Pyrococcus 
Kodakaraensis (Pfx) or Pyrococcus Furiosus (Pfu). In addition to a higher 
fidelity, both enzymes possess a 3‟ to 5‟ exonuclease activity by which they 
can exhibit a proofreading ability. In addition to this Taq will generate a 
product with a TA overhang, whilst the other two enzymes will generate a 
blunt ended product (Sambrook and Russell, 2001). 
The majority of DNA dependant polymerases sold commercially are produced 
using recombinant DNA technology. This has enabled a range of polymerases 
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to be generated which have specific mutations which enhance certain aspects 
of the behaviour of the polymerase (Merkens et al., 1995). Some 
modifications may enhance the ability of the polymerase to function in the 
presence of molecules normally regarded as PCR inhibitors, whilst others 
may have an influence on fidelity or the maximum possible size of the PCR 
product produced. 
Finally, it has often been noted that heating the initial PCR mixture from ice 
temperature to an initial denaturing step of around 95°C takes a finite amount 
of time. During this time the reaction mixture passes a warm phase below the 
annealing temperature of the reaction where non specific primer annealing 
may occur. This can lead to the generation of non specific PCR products, and 
can be eliminated using a PCR hot start (Chou et al., 1992). Although this can 
involve simply placing reaction tubes onto a pre heated thermal cycler, many 
polymerases have an inhibitory anti-polymerase monoclonal antibody 
included which breaks down at the higher denaturing temperatures an thus 
provides an automatic hot start.  
Adjuvants: Supplementing the PCR reaction mixture with additional 
components can often be useful. The following list of adjuvants is commonly 
used but not exhaustive. 
Adjuvant Concentration Notes 
Dimethyl Sulfoxide (DMSO) 2-10%  
Betain 1-1.5M Do not use Betain HCl 
Glycerol 1-10%  
Non ionic detergent 0.1-1% Triton X100, NP40, Tween20 
Formamide 1-10%  
BSA <10%  
Table 8: a selection of some commonly used PCR Adjuvants 
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The use of these additives can produce unwanted effects. Although DMSO 
can assist with PCR amplification, particularly in GC rich templates, it can 
reduce the activity of Taq at higher concentrations (Appendix III). Betain and 
Betain monohydrate form the basis of many commercial PCR enhancing 
solutions, although it should be noted that Betain hydrochloride is a PCR 
inhibitor (Appendix III). Glycerol can help with the reducing of secondary 
structure, as can many non ionic detergents. Non ionic detergents can also 
help to neutralise any SDS carried over from DNA purification protocols. 
Occasionally at higher concentrations, formamide appeared to reduce the 
activity of Taq (Appendix III). The use of BSA to stabilise PCR enzymes has 
proved valuable, particularly where DNA has been extracted from ancient 
sources and so may be contaminated with inhibitors such as melanin 
(Appendix III). 
In all cases, it is wise to optimise the concentration of adjuvants and to select 
the lowest possible concentration of any additives in order to reduce any 
negative effects the additive may have.  
 
2.8 Automated Fluorescent Sequencing 
 
The determination of genetic sequence is critical to the identification of 
genetic sequence variants and the identification of pathological mutations. 
Although chip based sequencing techniques are available, a common method 
of generating genetic sequence data relies of the Sanger di-deoxy 
sequencing. First published in December 1977 (Sanger et al., 1977), this 
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technique employs the use of both normal dNTPs and ddNTPs each labelled 
with a specific fluor. Thus, for any given nucleotide, the DNA synthesis can 
either continue following the inclusion of a dNTP or terminate with the 
inclusion of a fluor labelled ddNTP.  Since each ddNTP is labelled with a 
specific fluor, as shown below, the terminating nucleotide for each 
synthesised strand bear a fluor label. 
 
Figure 13: The ddNTP fluor labels used in automated fluorescent sequencing. 
 
Given that each fluor labelled DNA strand is of a different length depending on 
the point at which synthesis termination occurred, the separation of these 
strands by capillary electrophoresis will then allow the determination of DNA 
sequence as shown below in Figure 14. 
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Figure 14: A schematic representation of the Sanger di-deoxy sequencing method. 
 
The process of determining genetic sequence by this method has been 
simplified due to the availability of commercial kits and reagents such as Big 
Dye available from Applied Biosystems.  
 
Method 
 
The concentration of a purified PCR fragment was determined by UV 
spectrophotometry using a nanodrop ND1000. Then, using 500ng of DNA 
template, a sequencing reaction mixture was set up as shown in the table 
below. 
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Component Volume (μL) 
DNA temple  Volume equivalent to 500ng 
Big Dye v3.1 2 
ABI Buffer 4 
Primer 0.5 
dH2O To 20 
Total Volume 20 
Table 9: A standard sequencing reaction mixture 
 
The mixture is placed in a PCR tube and centrifuged briefly to collect the 
contents. It is then subjected to; 
95°C for 2 minutes and then, 
35 cycles of  
95°C for 30 seconds 
50°C for 10 seconds 
60°C for 4 minutes 
 
This was followed by rapid cooling to 4 °C which is held until hold until ready 
to purify. 
The tube contents were centrifuged briefly in order to prepare for the 
purification process. Firstly, 60μL of absolute ethanol is added to the tube. It 
was important to keep the final ethanol concentration between 67-71%. The 
tube was placed on ice for 30 minutes and centrifuged at 13000g for 30 
minutes at 4°C. The supernatant was carefully removed and the pellet, which 
was not always visible, was washed with 300µl of 70% ethanol.  The 
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supernatant was once again removed and the wash step was repeated. The 
pellet was dried under vacuum. The electrophoresis step using an ABI 
3130XL was performed by a Cardiff University core managed facility, central 
biotechnology services. 
 
2.10 SDS-PAGE Gel Electrophoresis  
The detection of proteins by SDS-PAGE gel electrophoresis is a technique 
widely used in biological research to separate proteins according to their 
electrophoretic mobility (Shapiro et al., 1967). The SDS gel electrophoresis of 
samples relies on those samples having identical charge per unit mass, and 
due to binding of SDS results in separation by size. 
Method 
 
An SDS polyacrylamide mixture was up as follows. 
 
Upper Gel: 2.4mls upper buffer, 1.252mls of 40% acrylamide, 6.14mls of 
dH2O, 0.1mls of ammonium persulfate and 0.01mls of TEMED. 
Lower Gel: 7.5mls lower buffer, 7.5mls of 40% acrylamide, 14.5mls of dH2O, 
0.3mls of ammonium persulfate and 0.03mls of TEMED. 
The ammonium persulfate solution was added to each mixture last as it 
initiates polymerisation. It was not until the lower gel had set that the upper 
gel had ammonium persulfate added. 
The percentage of acrylamide can be reduced in order to observe lower 
molecular weight products. 
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The SDS Page gel equipment used was a Bio-Rad mini protean II vertical gel 
system (Bio-Rad Laboratories, Hemel Hempstead, UK)   
The gel holder was assembled after all surfaces and glass plates were 
cleaned with 70% Methanol and dried thoroughly. Assembly occurred in 
accordance with the manufacturer‟s instructions. 
 The comb was placed the gel plates and a spot about 5-8mm below the 
bottom of the comb was marked. This was the level to which the lower gel 
was poured. The comb was removed and the lower gel poured.  
After 45 minutes a check was made for polymerisation then the top of the gels 
were rinsed with distilled water.  
The upper gel was then poured and the comb re inserted between the plates. 
After polymerisation the comb was removed and the gel clamped into the 
electrophoresis apparatus. 
The sample was increased to 30μL with running buffer and loading dye and 
then heated to 95°C for 5 minutes before loading on the gel. The sample was 
then loaded onto the gel, taking care to avoid spillage. A suitable protein 
marker ladder was also loaded onto the gel. 
The gel was then electrophoresed at between 100 and 180V until the loading 
dye front approached the bottom of the gel. Care should be taken to avoid the 
gel front bowing or distorting during electrophoresis, which is normally caused 
by a high current or voltage. 
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2.10 Western Blotting  
 
Western blotting is an analytical technique used to detect specific proteins in 
tissue homogenate, tissue culture supernatant or other sample capable of 
being electrophoresed on an SDS PAGE gel (Renart et al., 1979). It uses gel 
electrophoresis to separate proteins by the length of the polypeptide which 
occurs under denaturing conditions or by the protein structure in non 
denaturing conditions. All proteins are then transferred to a nitrocellulose 
membrane, where they are then detected using antibodies specific to the 
protein of interest. Prior to transferring protein onto the nitrocellulose 
membrane the protein must first undergo SDS PAGE gel electrophoresis as 
described in Experimental Methods. 
Method 
 
Electrophoresis Transfer using Wet Blots 
The gel and the nitrocellulose membrane were soaked in cold transfer buffer 
for 15 minutes to remove electrophoresis salts and detergents. In addition to 
this two filter papers of the same size as the gel were also soaked in transfer 
buffer. The transfer cassette is loaded as follows. 
A fibre pad, a filter paper, the SDS PAGE gel, the nitrocellulose membrane, 
another filter paper and another fibre pad. 
The cassette was loaded into the electrode module, ensuring it is loaded into 
the correct polarity orientation. The cassette was loaded into the buffer tank 
together with a magnetic stir bar and integral ice packs. The electrophoresis 
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tank was filled with transfer buffer to the appropriate level, and then placed on 
a magnetic stirrer at a low speed. The electrodes were attached to the tank 
and which was then run at 100 V for 1 hour. 
The membranes were rinsed four times with dH20 and blocked with 5% non-
fat milk-TBST solution for at least 30 minutes, although overnight is 
acceptable, while agitating on a mechanical rocker. The membranes may be 
stored in TBST at 4°C for up to 1 week.  
The blocking solution was removed and the membranes rinsed in TBST once.  
Then 500μL of 1/1000 dilution of primary antibody diluted in TBST was added. 
It was occasionally necessary to optimise the amount of antibody used for 
each protein of interest. The membranes were then left at room temperature 
for 30 minutes while shaking, after which they were then washed 4 times for 
five minutes per wash in TBST at room temperature. 
Then 500 µl of 1/1000 diluted conjugated secondary antibody was added. 
Again this occasionally needed optimisation. An incubation for 30 minutes at 
room temperature with shaking was then required. Again the membranes 
were washed four times for five minutes per wash with TBST at room 
temperature.  
The membranes were developed using an ECL kit (GE Healthcare, 
Amersham, UK) and processed using automatic developer. A variety of 
exposure times are used to determine the best signal to noise ratio for the 
final photograph. Typically 15 seconds, 1 minute and 30 minutes were used. 
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Chapter 3 
The Investigation of C5 
Deficiency in a South African 
Patient 
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3.1 Introduction 
 
Complement component C5 deficiency is an infrequently observed 
complement terminal pathway deficiency, with less than 100 cases of C5 
deficiency having been reported from ethnically diverse families (Lopez-Lera 
et al., 2009, Boelaert et al., 1985, Pfarr et al., 2005). The cases of C5 
deficiency have been reported amongst Afro Americans, South Americans, 
South Africans and Moroccans (Wang et al., 1995). This chapter describes 
the molecular investigation of a South African Xhosan woman in her early 
thirties, who has had two attacks of meningitis caused by Neisseria 
meningitidis. A diagnosis of C5 deficiency was made by immunodiffusion 
assay and by demonstrating that no lytic activity was present in a haemolysis 
assay. 
The patient has been prescribed monthly bicillin injections and has been 
observed for over ten years. She has suffered no further attacks since 
diagnosis.  
Previous work in this laboratory together with Ms Claire Edwards (University 
of Surrey, M.Sc. 2006) focused on sequencing all 41 exons present in 
genomic DNA. Five sequence variations were observed, most significantly a 
heterozygous nonsense mutation in exon 1 c.84C>T which lead to premature 
termination (p.Q19X). This mutation has been reported previously in two Afro-
American families (Wang et al, 1995). This is shown below in figure 15. 
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Figure 15. The published C5 exon 1 defect p.Q19X observed in the C5 deficient patient 
 
The location of the defect on the first exon suggests that this is a null-allele 
and that no protein with any characteristics of C5 would be produced (Chang 
et al., 2007, Chan et al., 2007) 
Another coding sequence variation was identified in exon 7 [c.754G>A; 
rs112959008], which causes a substitution of alanine at position 252 for a 
threonine [p.Ala252Thr].  This variation occurs within the alpha-2-macroglobin 
domain in the C5b section of the C5 molecule (DiScipio et al, 1998). The 
sequencing electropherogram is shown in figure 16 below. 
  
Figure 16. The c.754G>A sequence variation observed on C5 exon 7. The figure shows exon 
7 sequenced (A) in the forward direction and (B) the reverse direction. The location of the 
variation is marked 
 
In addition, two intronic sequence variations were observed in intron 25 and 
are shown in Figure 17. These were both close to exon 26 and are 
heterozygous T>G substitutions [IVS25-18T>G and IVS25-22T>G].  
A further sequence variant was a homozygous substitution of G for a T at 
position – 12 within intron 32. [IVS32-12G>T] This is a known polymorphism 
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listed as rs10985112 and is also shown in figure 17 alongside the intron 25 
variation. 
 
Figure 17. The C5 polymorphisms observed in introns 25 and 32 for the patient. 
 
To summarise, five sequence variations were identified (table 10). Only 1 of 
these, the truncating mutation in exon 1 (p. Q19X) can be considered 
pathogenic (Wang et al., 1995). The other 4 are of unknown clinical 
significance. The missense mutation in exon 7 is a relatively conservative 
substitution that has been identified previously on a single allele from 1000 
genomes originating from the Bantu population in Central and South Africa 
and has been deposited in the database (dbSNP XML build 135) as 
rs112959008. The two intronic sequence variants upstream of the canonical 
splice acceptor site of exons 26 have not been previously reported and are 
also of unknown clinical significance, as is the polymorphism rs10985112 in 
intron 32.The possibility that a pathogenic mutation had been missed and was 
located elsewhere in the C5 gene was therefore considered. This chapter 
includes the results of this sequencing analysis. The chapter also includes the 
description of bioinformatic analyses of the identified sequence variants. In 
addition efforts to optimise RT-PCR amplification of C5 from human cell types 
are presented. 
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Location Position Change dbSNP Reference 
Exon 1 c.84C>T Q19X rs121909587 
Exon 7 c.754G>A A252T rs112959008 
Intron 25 c.32311-18T>G Unknown None 
Intron 25 c.32311-22T>G Unknown None 
Intron 33 c.4163-12C>T Unknown rs10985112 
Table 10.  The sequence variations observed on the patient C5 gene 
 
3.2 Materials and Methods 
The primers used for PCR amplification and their respective annealing 
temperatures were designed with primer3 software and are shown below in 
table 11.  
 
3.2.1 Bioinformatics 
 Four prediction software packages were used to analyse mutations, these 
programs can be classified either as splicing prediction programs or protein 
function programs. 
RESCUE-ESE: This resource is web based and available at 
http://genes.mit.edu/burgelab/rescue-ese/ .  
ESEFINDER: This is a web based resource at http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi  (Cartegni et al., 2003) 
PolyPhen-2: This resource is at http://genetics.bwh.harvard.edu/pph2/  and is 
used for predicting the possible effect of an amino acid change on the 
structure and function of a human protein.  
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SIFT: This is a web based resource available at http://sift.jcvi.org/ which 
allows the end user to check for changes in protein functionality using multiple 
alignment data to predict tolerated substitutions or potential defects.  
Putative promoter sequences were analysed analyses using MatInspector 
software at www.genomatix.de. CpG island motifs were identified using 
EMBOSS software available via the web server at 
http://www.ebi.ac.uk/Tools/emboss/cpgplot/index.html 
 
3.2.2 Identifying secondary structure in C5 mRNA 
 
The C5 mRNA sequence was examined using RNAfold software available at 
http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi for secondary structure by 
calculating lowest mean free energy. Data on centroid structure and partition 
functions was also obtained with this software. 
 
3.2.3 The design of PCR primers for amplifying C5 mRNA 
 
The mRNA sequence was examined for repetitive Alu, LINE and SINE 
elements using www.repeatmasker.org.  GC content of C5 mRNA was 
analysed using Vector NTI software (Invitrogen, UK) for successive DNA 
segments of 10bp. Primers were initially designed with primer3 software 
available at http://primer3.sourceforge.net/, with GC content of 50% selected 
as optimum (Regions with a GC content of<35% or >65% were excluded). 
The proposed primers positions were adjusted manually to avoid SNPs and 
regions with high secondary structure complexity. Full length mRNA was 
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amplified in 7 overlapping fragments using the primers listed in table 11 
below. 
 
Primer Sequence %GC Content 
C5 cDNA 1F ATCCGTGGTTTCCTGCTACC 55 
C5 cDNA 1R TTTGCATTGCTGTTTGCATC 40 
C5 cDNA 2F AAAGTAGTCACTGAGGCTGACG 50 
C5 cDNA 2R AGACACAGTTTGGCCTGGAG 55 
C5 cDNA 3F TCACAGGAGAACAGACAGCAG 52 
C5 cDNA 3R CAGTGTTTGAAATGCCAACG 45 
C5 cDNA 4F TTTCCAGAAAAGCTGGTTGTG 43 
C5 cDNA 4R TAGCACTTCCACCCTTCCAC 55 
C5 cDNA 5F CTGGAAACAGGAAATCATTGG 43 
C5 cDNA 5R CCACCTCCATACCTCTGCTC 60 
C5 cDNA 6F ACACTGGTACGGCACGTATG 55 
C5 cDNA 6R CGGCTCCTTCACAGACTTTTC 52 
C5 cDNA 7F CAGTCCTGCCACTTTCACAG 55 
C5 cDNA 7R CAGCAAACATTCCTGAGTGG 50 
Table 11. The primers designed for the amplification of C5 cDNA in 7 fragments 
 
3.2.4 Optimising the amplification of C5 mRNA 
 
The reverse transcription reactions were performed as described in materials 
and methods section 2.5. The secondary structure reducing additives were 
used at a volume of 5µL in a 20µLreaction and are as follows; 
A. dH2O – This was used as a control to maintain constant volume. 
B. DMSO (Fisher, UK) – A working concentration of 20% was used.  
C. Betain (Sigma Aldrich, UK) – Betain and Betain Monohydrate are 
thought to reduce secondary structure,  
D. Formamide (Oxoid, UK)– A final concentration of 10% was used. 
E. Triton X100 (Fisher, UK) – A final concentration of 1% was used.  
F. BSA (Invitrogen, UK)–A final concentration of 20% was used. 
G. Invitrogen PCR Enhancer Solution (Invitrogen, UK) – This is a 
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commercially available solution containing a proprietary mix of components. A 
final concentration of 10% was used. 
The fidelity of the reverse transcriptase in this modified reaction was assessed 
using the housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase 
(GapDH). An additive was considered unacceptable if a PCR amplification of 
GapDH cDNA produced either non-specific PCR products or significantly 
reduced quantities of the GapDH amplicon. 
 
3.2.5 The selection of appropriate cell types for C5 cDNA amplification 
 
Buffy coat was prepared from a sample of 15mls of whole blood as described 
in materials and methods. The following cell types were then enriched and 
used for the preparation of mRNA and corresponding cDNA; 
(1) Buffy Coat: This was used directly for mRNA production and served as a 
relative control. (2) EBV Immortalised B Cells: Buffy coat from a healthy 
volunteer was co-cultured with a sample of live EBV virus derived from B95-8 
cells. Cyclisporin A was added to reduce T cell proliferation. The process of 
transformation took 4 to 6 weeks.  Activated EBV transformed B cells were 
produced by co-culturing with L cells and an anti human CD154 antibody. 
(3) Monocytes: These were prepared by placing buffy coat in 15mls of RPMI 
F10 media (Invitrogen, UK) in a 25cm2 tissue culture flask overnight which 
resulted in monocytes becoming adherent. The remaining cells were 
aspirated and the monocytes then harvested. 
(4) Neutrophils: These were isolated as described in materials and methods. 
.  
61 
 
3.3 Results 
 
3.3.1 Extended Genomic Sequencing 
 
The 5‟ untranslated regions (UTRs) of genes may contain elements capable 
of regulating gene expression, particularly translation. However, the C5 gene 
5‟UTR is 31bp in length, which is a relatively short UTR and is not predicted 
to have a significant effect on gene expression. Sequencing the patient‟s 
genomic DNA across this region did not identify any variation.  
3‟UTRs of genes contains elements which may affect the mRNA stability. The 
C5 gene 3‟UTR is 401bp (www.ensembl.org) and contains a number of 
known sequence variants (table 12) for which there is no information 
concerning their possible effect on C5 expression.  Sequencing the patient‟s 
genomic DNA that included the 3‟UTR did not identify any of these rare 
alleles nor find additional changes. These results confirm that no other 
mutations were present within the C5 transcript sequence.  
Location 
(from stop codon) 
SNP Identifier Population Genetics 
+78 rs147540583 No Data 
+111 rs141560628 No Data 
+301 rs148353209 No Data 
+324 rs118181017 0.008 CHB / JPT 
+327 rs144332635 No Data 
Table 12: The location of sequence variations in the C5 3‟ flanking region, together with SNP 
reference number and available gene frequency data. (CHB) Chinese living in Beijing (JPT) 
Japanese living in Tokyo 
 
Sequencing analysis was then extended to include the C5 promoter region.  
This region has only been partially characterised (Carney et al., 1991) 
Putative sequence elements including a TATA-like element and CCAAT box 
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were identified together with a number of transcription factor binding sites 
(Figure 18), However, the minimal promoter sequence was not defined 
through functional analysis  and non of these elements have been shown to 
function in vivo.  
Sequence upstream of C5 was re-analysed by in silico methods. Using 
MatInspector software at www.genomatix.de, a TATA-less core promoter was 
identified at position -379 to -429 (relative to the translation ATG start site). 
Although this seemed too far upstream from the reported transcriptional start 
site at -31 and was likely to be artifactual, it did provide the impetus to explore 
regions further upstream and in particular look for CpG islands. Vertebrate 
CpG islands (CGIs) are short interspersed DNA sequences that deviate 
significantly from the average genomic pattern by being GC-rich, CpG-rich, 
and predominantly nonmethylated. Most, perhaps all, CGIs are sites of 
transcription initiation, shared DNA sequence features adapt CGIs for 
promoter function by destabilizing nucleosomes and attracting proteins that 
create a transcriptionally permissive chromatin state. 2Kb of sequence 
upstream of C5 was therefore examined for CpG island motifs using 
EMBOSS software available via the web server at 
http://www.ebi.ac.uk/Tools/emboss/cpgplot/index.html. A CpG island motif 
was located at position -1725 to -1570, relative to the translation ATG start 
site. These features are shown in figure 18 below 
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 Figure 18. A diagram representing the relative positions of specified sequence elements 
involved in enhancing gene transcription. 
 
 
In addition, a list of known sequence variations within this region and their 
respective positions were generated from www.ensembl.org data and shown 
below in Table 13. 
 
 
Location 
(from start codon) 
SNP Identifier Population Genetics 
-202 150172957 No Data 
-227 138666345 No Data 
-340 114156353 0.008 YRI 
-419 41307964 0.008 YRI 
-428 36223102 0.042 YRI 
-705 148922946 No Data 
-835 36223103 No Data 
-930 36223100 Venter: USC 
-942 5900469 No Data 
-957 79187303 0.500 USC 
-959 62578436 0.500 USC 
-1126 57815396 No Data 
-1416 138308342 No Data 
-1553 36223437 0.058 CEU 
-1705 78945889 No Data 
-1884 36223436 0.067 CEU 
Table 13: The location of sequence variations in the C5 5‟ flanking region, together with SNP 
reference number and available gene frequency data. (YRI) Yorubi living in Ibidan. (USC) US 
Caucasians and (CEU) Utah resident of central European ancestry 
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This extended region of genomic DNA was amplified by PCR and subjected to 
automated fluorescent sequencing. No additional sequence variants were 
detected and none of the published rare alleles were present. These results 
provided strong evidence that no additional mutations are present within the 
C5 gene. It was therefore decided to re-examine those mutations already 
identified by in silico methods. 
 
3.3.2 Bioinformatics 
 
The semi-conservative substitution in exon 7 (p.Ala252Thr) replaces a 
hydrophobic amino acid residue for a polar uncharged amino acid residue. A 
phylogenetic comparison between human C5, and other species indicated 
that Ala252 is highly conserved (figure 19). A phylogenetic comparison 
between human C5, and C5 from macaque, marmoset, giant panda, cow, pig, 
rat, dog, opossum, zebra finch, chicken and frog was made. The comparison 
between Human and Gorilla C5 does show a conservative change from 
Alanine to Leucine, although the gorilla data is derived from one individual. 
The predicted consequence of this change on protein function was 
investigated using different prediction software (PolyPhen2, SIFT). Using 
PolyPhen2, the p.Ala252Thr change was considered to be possibly damaging 
to protein function, with a score of 0.690 (on a scale of 0.000 -1.000). The 
phylogenetic comparison result below in figure 19 implies that position 252 
(indicated by a black box) is highly conserved. An examination of the species 
compared revealed that the amino acid residue was conserved in the 
Japanese puffer fish (fugu rubripes) but not in the spotted green pufferfish 
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(Tetraodon nigroviridis). The spotted green pufferfish C5 protein has a valine 
at the equivalent 252 position. 
This amino acid change was also considered deleterious using SIFT, a 
prediction software based on the degree of conservation of amino acid 
residues in sequence alignments derived from closely related sequences.  
 
 
Figure 19. A comparison of human C5 against those of other species listed above. The 
comparison is centred on position 252. 
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Each mutation was further evaluated for possible effects on C5 mRNA 
splicing using RESCUE-ESE and ESE-FINDER software.  
The mutated base c.754G is 5bp from the 3‟end of exon 7 and so an effect on 
splicing was considered a plausible explanation; perhaps through disrupting 
an exonic splicing enhancer (ESE) sequence. ESEs are pre-mRNA cis-acting 
elements required for splice-site recognition and have been shown to bind SR 
(serine/arginine) proteins that are involved in regulating and selecting splice 
sites in eukaryotic mRNA. Interestingly, ESEfinder predicted the loss of a 
putative SR40 binding site in the mutated sequence, indicating that this 
mutation may affect the correct splicing of exon 7, an illustration of splice site 
for the normal and mutated sequence are shown below in figure 20. 
 Figure 20. A representation of splicing motifs and their relative strengths for normal exon 7 
and mutated 754G>A sequence. The blue bar represents the position of the exon. The height 
of each bar is directly proportional to the relative splicing strength. The position of each bar 
indicates the nucleotide sequence of each splicing motif. The varying colour of each bar is for 
illustration purposes only. 
 
The three remaining intronic sequence variants were also analysed. The 
c.3231-18T>G and c.3231-22T>G variants in intron 25 are within the 
polypyrimidine region of the splice acceptor site and could potentially interfere 
with correct splicing of exon 26 (Aguilar-Ramirez., 2009). Neither sequence 
variant was predicted affect the strength of the cognate splice acceptor site of 
exon 26, or create or abolish putative ESE motifs. However, both T>G 
transversions were predicted to result in the creation of possible cryptic splice 
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acceptor sites (ApG), as shown in figure 21 below, upstream of exon 26. 
Recognition of these sites by the cells splicing machinery would, in theory, 
result in an in-frame insertion of six and 7 amino acids respectively.  
 
 
Figure 21. A representation of splicing motifs and their relative strengths for normal intron 25 
and the two mutated intron 25 sequences. The -18 sequence variation is shown in the upper 
panels A and the -22 sequence variation is shown in the lower panels B. The blue bars 
represents the position of the exon. The blue bar represents the position of the exon, with the 
nucleotide sequence leading to the six and seven amino acid inclusions shown in the boxed 
area preceding the exon. The height of each bar is directly proportional to the relative splicing 
strength. The position of each bar indicates the nucleotide sequence of each splicing motif. 
The varying colour of each bar is for illustration purposes only. 
 
 
 
The c.4163-12C>T polymorphism in intron 32 also lies within the 
polypyrimidine tract of the splice acceptor site. The replacement of one 
pyrimidine for another would not be expected to have an effect on splicing of 
exon 32 and in silico analyses also predicted a negligible reduction in the 
strength of a putative ESE, and no effect on the strength of the splice 
acceptor site as shown in figure 22 below. 
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Figure 22. A representation of splicing motifs and their relative strengths for normal intron 32 
sequence and mutated c.4163-12C>T sequence. The blue bar represents the position of the 
exon. The height of each bar is directly proportional to the relative splicing strength. The 
position of each bar indicates the nucleotide sequence of each splicing motif. The varying 
colour of each bar is for illustration purposes only. 
 
 
 
3.3.3 C5 mRNA secondary structure 
 
The theoretical effect of the c.754G>A change on the secondary structure of 
the mature C5 mRNA was also investigated. C5 mRNA secondary structure 
was analysed using RNAfold. A comparison of the mean free energy 
algorithm for both C5  Normal mRNA and the C5 A252T mRNA  is depicted in 
figure 23 and shows a high degree of secondary structure within the C5 
mRNA molecule  and subtle alterations due to  the c.754G>A change. 
However, when the algorithm was expanded to include a centroid function, 
which calculates the minimum possible distance between branched structures 
in accordance with the Boltzmann equation, the change to predicted mRNA 
structure was pronounced, as shown in figure 24 below. Whether these 
alterations in the secondary structure due to a single base substitution reflect 
the true nature of mRNA in vivo is open to question. The possibility that an 
increase in secondary structure may interfere with gene expression, for 
instance, by interfering with ribosome progression during translation remains 
a theoretical possibility 
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Figure 23. A comparison between (A) the 
reference C5 mRNA sequence and (B) the 
C5 mRNA exon 7 variation sequence. 
Selected changes to secondary structure 
are highlighted within the red boxes. 
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Figure 24. The secondary structure predicted with a centroid function for (A) the reference C5 
mRNA sequence and (B) the C5 C84T variant sequence. 
 
 
3.3.4 The optimised RT-PCR amplification of C5 mRNA  
In silico analyses indicate possible effects of the sequencing variants in exon 
7 and intron 25. A direct study of these sequence variants on C5 mRNA 
stability and/or splicing would require efficient amplification by RT-PCR 
A method of amplifying C5 cDNA has been described by Delgado-Cervino 
(2005), and utilises a series of overlapping PCR reactions. This method was 
initially used to investigate the mutations in exons 1 and 7. We and others 
(personal communication) met with difficulties amplifying the 5‟ end of the C5 
cDNA, encoded by the first 10 exons, and a second round of PCR using 
nested primers was required, however, this often led to the amplification of 
aberrantly spliced transcripts. This may be due in part to the length of C5 
mRNA, which is approximately 5kb long. However, as described above, it is 
also possible that a highly complex secondary structure may impede the 
procession of reverse-transcriptase and or polymerase during RT-PCR. 
Therefore, a new protocol for C5 was developed. Initially the reduction of 
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secondary structure was attempted using a reverse transcriptase with a high 
reaction temperature. The enzyme Thermoscript RT (Invitrogen, UK) was 
reported to work up to 65°C. However, this proved unsuccessful. 
A new set of primers were therefore designed. Firstly, using sequencing utility 
software RepeatMasker, human C5 cDNA was shown not to be harbour any 
repetitive sequence elements. Primers were selected based on their GC 
content and were located in regions of low secondary structure complexity 
and did not overlap with known SNPS. Secondly a series of different 
additives, including those known to relieve secondary structure were tested. 
Initially, these were tested on a control GapDH PCR amplification to check for 
enzyme fidelity changes. The GapDH PCR products are shown on an 
agarose gel in figure 25 below. Addition of DMSO, Betain, formamide or Triton 
X100 resulted in reduced yield and non-specific amplification, whereas BSA 
and the PCRx enhancer produced a specific product with comparable yields to 
the water control. Since Invitrogen PCRx additive is known to relieve difficult 
regions of secondary structure, this additive was used in subsequent 
amplifications of C5. 
 
Figure 25. The amplification of the GapDH control sequence using cDNA templates with 
reverse transcription steps modified with (1) dH2O (2) NTC (3) No Additives (4) DMSO (5) 
Betain (6) Formamide (7) Triton X100 (8) BSA (9) Invitrogen PCRx enhancer 
 
These amplification conditions were then used to amplify C5 using 35 PCR 
cycles from HepG2 cells, which are a known to express high levels of C5. 
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Full length C5 cDNA was successfully amplified by RT-PCR amplified in 7 
overlapping reactions) as shown in the figure 26 below, confirming the utility 
of this method. This amplification method was then applied to cDNA obtained 
from different cell-types.  
 
 
Figure 26. The amplification of C5 cDNA from a HepG2 cDNA template reverse transcribed in 
the presence of Invitrogen PCRx enhancer solution. Each PCR product represents a segment 
of C5 cDNA amplified by the primers in Table 11, and have a corresponding numbering 
shown in the figure. 
 
3.3.5 Appropriate source material for the amplification of C5 mRNA  
 
Two PCR reactions were used for a semi-quantitative comparison of C5 
expression between different cell preparations. These reactions corresponded 
to fragment 1 and fragment 5 of C5 cDNA as described above. Fragment 5 
was selected as it was robust and suitably distal from fragment 1 which was 
included to provide an assessment of efficient cDNA synthesis.  
Amplification of C5 cDNA from monocytes and EBV immortalised B cells was 
poor and discounted as monocytes and EBV immortalised B cells both 
appeared to produce C5 mRNA at comparatively low levels as shown in a 
representative figure 27 below 
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Figure 27. A representative amplification of C5 cDNA by (A) monocytes, (B) EBV 
immortalised B cells and (C) activated EBV immortalised B cells. Faint bands were 
occasionally observed for the monocyte template and are shown in Lanes 1 and 2. Normal 
EBV immortalised B cells did not give a distinct PCR product as shown in gel B. Activated B 
cells rarely gave a distinct PCR product, an example of which is seen in Lane 3.  
 
The PCR amplification of C5 cDNA from buffy coat and Neutrophil derived 
cDNA templates gave a more abundant product as shown in figure 28 below. 
Comparison of the relative intensity of these fragments indicated that full 
length cDNA was efficiently synthesised in from both cell preparations 
suggesting that full length cDNA had been reverse transcribed efficiently for 
each template.  
 
Figure 28. The upper panel shows representative amplification of selected C5 cDNA 
fragments for both buffy coat (left) and Neutrophil (right) derived cDNA templates 
The lower panel shows a graphical representation of Densitometry data for each of the PCR 
amplifications for buffy coat and Neutrophil derived template.  
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3.4 Discussion 
 
The genomic sequencing of all 41 exons and promoter region constitutes less 
than 10% of the total C5 gene, and therefore a causative mutation perhaps 
embedded deep within an intron may have been missed. However, five 
sequence variations were identified in this South African woman with C5 
deficiency. One of these is a published nonsense mutation in exon 1. 
Unfortunately for the remaining variations, particularly the intronic mutations, 
no suitable tissue material was available from the patient in order to directly 
study potential effects on C5 mRNA processing and therefore the molecular 
mechanisms that result in C5 deficiency in this patient remain speculative. 
The strongest candidate is c.754G>A in exon 7. Genomic sequencing of the 
patient‟s offspring demonstrated that the exon 1 and exon 7 mutations 
segregate independently, thus showing they exist on separate alleles in 
patient genomic DNA.  The sequence variation in exon 7 has been identified 
in one additional allele from 1000 genomes originating from the same 
population as the patient described here. Whilst it remains possible that this is 
a rare SNP of no clinical significance, it may also prove to be a relatively 
common cause of C5 deficiency in this population.  
It may exert its effect on C5 expression via a number of possible mechanisms, 
it is unlikely that stable but inactive C5 with an Ala252Thr substitution is 
produced as this would still be detectable via a polyclonal antibody based 
immunoblot, and no such protein is observed (data not shown). It may inhibit 
protein secretion from the cell, but this too may be unlikely as C5 would be 
detectable from cells that have undergone lysis.  
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Undetectable levels of C5 could be caused by protein instability, or mRNA 
instability. The latter may result from mis-splicing involving exon 7 (Graveley 
et al., 1998, Graveley et al., 2008).  Furthermore, the profound effect that 
c.754G>A may have on mRNA folding is intriguing and outcome of this 
mutation suggests another possibility whereby translation inhibition and 
therefore mRNA stability is a possible. 
In order to gain an insight into the nature of the A252T C5 mutation and the 
mechanisms leading to deficiency it may be possible to clone functional C5 
and ligate it into an expression vector to allow exogenous expression. Site 
directed mutagenesis may then allow the creation of a plasmid containing 
A252T mutation. Protein and mRNA studies on cells containing either the 
normal C5 or A252T C5 plasmid may yield important data regarding the 
molecular mechanism of deficiency for this mutation.  
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Chapter 4 
The characterisation of a large 
C7 genomic defect present in the 
Irish population 
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4.1 Introduction 
 
A study of known genetic defects responsible for C7 deficiency revealed that 
the genetic defects responsible are very heterogeneous (Thomas et al., 
2012).  
To date there are over 25 different C7 gene sequence variations that have 
been deposited in the Human Gene Mutation Database [HGMD] 
http://www.hgmd.cf.ac.uk/ac/index.php.  Mostly, these are restricted to 
individual families, although occasionally the same C7 defect is found in 
several unrelated families living within a particular community such as the 
pathogenic G357R change found in Moroccan Jews living in Israel (Fernie et 
al., 1997b).  
A gene deletion defect was suspected following the regional failure to PCR 
amplify exons 8 and 9 (shown here in figure 29, and supported by Southern 
Blot analyses).   
 
Figure 29. The regional failure of PCR for exons 8 and 9 and using a control DNA sample and 
a heterozygous sample (shown in the first two lanes for each exon) and two deletion defect 
positive subjects. 
 
Direct demonstration of the deletion in heterozygotes is prevented by the 
amplification of exons 8 and 9 from the normal allele (Figure 29 above). 
The work described in this chapter includes investigations to fully characterise 
the breakpoints of the deletion. Using this information a method to screen for 
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it in homozygotes and heterozygotes was developed. A possible mechanism 
of deletion is also discussed. 
 
4.2 Methods 
 
4.2.1 Patients 
 
The subjects reported in this study were members of four unrelated Southern 
Irish families; within each family the proband was diagnosed because of 
meningococcal infections. There is no evidence that any of the families are 
related. Families 1 and 2 have been described previously (Egan et al., 1994; 
Fernie et al., 1997b); Family 3 has been reported as Family A (O‟Hara et al., 
1998). Fresh blood samples were obtained from two members of Family 3 for 
this study. A fourth family that has not been reported previously and includes 
a single C7D patient, parents and two C7 sufficient siblings was also 
investigated in this study. 
 
 
4.2.2 PCR walking and amplification across the deletion boundaries 
 
The conditions for PCR amplifications are as described in Materials and 
Methods. The primers used are listed in Table 14 
 
Primer Name Sequence 
Intron 7 Region 1F  CAATATCATGTCACTGCACTTCAGC 
Intron 7 Region 1R  GCCTCTAGCATTTGCATTTAAGAAG 
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Intron 7 Region 2F  CAAAGCCCTTATTACCTTGAAATCTTC  
Intron 7 Region 2R  TCAGATTTCTCAAGAGGAAGGTTTTAG 
Intron 7 Region 3F  GAGGCTTTTTAGATGGTGCATGA 
Intron 7 Region 3R  GCTCCATAGTCAGTTTCTCAGTCATAAA  
Intron 9 Region 1F  GGAAGCATCAGGTGATTTGTTAAAA  
Intron 9 Region 1R  TCTCTTAACCTCATGATCCACCCA  
Intron 9 Region 2F  AGAGATTGCTTAATGGGTATAAACCTGT  
Intron 9 Region 3F  ATCATGAGGTTAAGAGATCGAGACCA  
Intron 9 Region 2+3R  CCTGACTGTGCTATCAAACACTAGAATT  
Table 14. The primer sequences used to restrict the potential size of the C7 gene deletion by 
gene walking 
 
The locations of the gene walking PCR fragments are shown in figure 30, and 
following the restriction of the size of the potential deletion defect using this 
method, and attempt was then made to amplify across the defect using the 
sense and antisense primers in table 9 that most closely bracket the deletion 
defect. 
 
 
Figure 30. The locations of PCR gene walking fragments and the region across the deletion 
defect for which amplification is desired. 
 
 
4.2.3 The routine identification of the large C7 genomic deletion 
 
The deletion was screened using a duplex PCR method using the primers 
listed below. The cycling conditions were an initial denaturing step of 95°C for 
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2 minutes then 35 cycles of 95°C for 30 seconds, 55°C for 30 seconds and 
72°C for 30 seconds. 
Primer Name Sequence 
Deletion Defect F TCTCCACATTATATTGTTCACAAAGTGG 
Deletion Defect R CGTCTTCATTGTTAGCTGTGTTTTCA 
Normal Allele F CTTCATTATAAAGTAGCTTCACCTGCAA 
Normal Allele R TCTGAGGGAACTGCAGATTTCTTAG 
Table 15. The primers used for the routine detection of the C7 deletion defect 
 
4.2.4 Gene Nomenclature 
 
For this study, C7 exons   are numbered 1-18. Historically, exons were 
numbered 0-17. Nucleotides are numbered from the initiating methionine of 
the Coding Reference sequence for human C7 (NM_000587). This is 
consistent with the guidelines of the HGVS (www.hgvs.org/rec.html). 
 
4.3 Results 
 
Our initial attempts at long range PCR to amplify across the deletion using 
primers in exons 7 and 10 were unsuccessful. We therefore decided to use 
PCR-walking to localize the breakpoints. DNA from the homozygous C7D 
patient of Family 1 was analysed using the primer pairs (listed in Table 10) 
that were progressively proximal to the deleted exons. Positive amplification 
indicated that the sequence was normal while failure to amplify indicated 
deleted sequence. The results are shown in Figure 31 below. 
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Figure 31. The successful amplification of each of the PCR walking amplification for primers 
listed in table 9. The first lane (left to right) is a DNA ladder. The land 2 to 4 are the 3 intron 7 
fragments and the lanes 5 to 7 are the intron 9 fragments. 
 
 Using this strategy, it was determined that the deletion could be no longer 
than 7317bp, based on the consensus C7 gene sequence obtained from the 
Sanger Institute. These results were consistent with the previous estimations 
of O‟Hara et al who concluded that the 5‟ boundary was 800-1400bp 5‟ of 
exon 8 and the 3‟ boundary 1200-1800bp 5' of exon 10  (O‟Hara et al., 1998). 
Primers: intron 7 region 3F and intron 9 region 2+3R were then used to 
amplify across the boundary as shown in figure 32 below.  
 
 
Figure 32. An amplification across the deletion boundary for (1) a heterozygote, (2) A deletion 
defect homozygote, (3) a normal control and (4) a no template control. 
 
Although extensive non-specific amplification occurred, a 429bp product was 
visible in a homozygous C7D individual and a heterozygote but not control 
DNA. DNA sequencing is shown in figure 33 below.  
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Figure 33. A sequencing figure describing the identity of the deletion and novel 8bp inclusion. 
This sequence was consistent between each of the four families examined. 
 
Alignment with normal C7 demonstrated that the deletion was a complex 
rearrangement consisting of a 6369bp deletion and, interestingly, the insertion 
of a novel 8bp sequence. [c.738+1262_1270-2387delinsGCAGGCCA].  
 
4.4 Screening for the deletion using a duplex PCR 
 
A duplex PCR for the simultaneous amplification of normal sequence and 
across the deleted sequence was established using additional primer pairs 
listed in table 10. One set of primers [Deletion Defect F and Deletion Defect 
R] were used to amplify across the deletion and result in a 302bp product 
when amplifying across the deletion. Amplification of normal sequence using 
these primers cannot proceed using specified cycling conditions, because the 
product is too long. The other set of primers [Normal Allele F and Normal 
Allele R], located within exon 8 and therefore within the deleted sequence.  
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These primers amplify a 257bp product when a normal template of the C7 
gene is present.  
Using this method we analysed the proband and relatives in our families. The 
result of screening in Family 2 is shown in Figure 35. An investigation of ten 
haplotype markers on both the C6 and C7 genes on each of the family 
members implied that the deletion defect was consistent with a particular 
haplotype (Fernie et al., 1997a). This haplotype indicated that the deletion 
defect status for each family member, from left to right in figure 34 was two 
heterozygotes, three deletion homozygotes, three heterozygotes and then two 
normal individuals. This matches the result shown by routine screening duplex 
PCR. 
 
 
Figure 34. A duplex PCR for the routine detection of the C7 deletion defect for family 2  
 
 A fourth unrelated family where the deletion defect was suspected was also 
investigated. The proband was diagnosed as C7D post mortem. The results 
are shown in Figure 35 below, and indicates that not only was the proband 
homozygous for the deletion defect, but several heterozygotes are present 
within family 4. 
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Figure 35. A duplex PCR for the routine detection of the C7 deletion defect for family 4. The 
figure (left to right) shows a DNA ladder, two heterozygotes, a deficient patient, a 
heterozygote and an unaffected individual. 
 
 
4.5 Discussion 
 
The sequencing of PCR fragments amplifying across the DNA deletions in the 
index cases in Families 1, 2 and 3 revealed identical breakpoints and 8bp 
insertion. In addition, investigations of the affected member of Family 4 also 
confirmed homozygous deletion. Complete characterisation of the DNA 
sequence of the deletion enabled us to develop a simple duplex PCR-based 
assay to test for the presence of both one non-affected allele and one affected 
allele (Thomas et al., 2012).  We also analysed the index case from Family 1 
who is heterozygous for the deletion defect and a splicing defect in intron 1 
(c.7-1G>A). Both deletion-positive and deletion-negative DNA fragments were 
amplified, thus confirming the patient is compound heterozygote. 
An investigation into the origin of the C7 deletion defect was conducted using 
in silico methods. This work was performed in collaboration with Dr Nadia 
Chuzhanova in Department of Medical Genetics Cardiff University. Dr 
Chuzhanova is credited with generating the final hypothesis for the origin of 
the deletion defect. 
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Initially, the sequences flanking both breakpoints were screened for the 
presence of direct repeats, inverted repeats and symmetric elements listed in 
Appendix IV by means of complexity analysis (Gusev et al., 1999).  
The program RepeatMasker was used to determine whether any of the 
repetitive sequence elements identified by means of complexity analysis were 
either Alu or LINE elements. In addition, ±10bp flanking each breakpoint were 
screened for the presence of 37 DNA sequence motifs (or their complements) 
of length ≥5bp known to be associated with site-specific 
cleavage/recombination, high frequency mutation and gene rearrangement 
(Abeysinghe et al. 2003) as well as various „super-hotspot motifs‟ found in the 
vicinity of micro-deletions/-insertions and indels (Ball et al., 2005). These DNA 
sequence datasets were also screened for the presence of 15 additional 
recombination-associated motifs (plus their complements) identified by Cullen 
et al. (2002) plus a CCTCCCT motif associated with a classical meiotic 
recombination hotspot (Myers et al. 2005; Myers et al. 2006). The motifs 
examined are listed in Appendix IV. 
Inspection of the C7 genomic sequence identified five Alu sequences (AluJo, 
AluSx, AluSg, AluSc and AluSx) in the vicinity of the deletion/insertion 
breakpoints. The orientations of these highly homologous sequences (1-5) are 
denoted by arrows in Figure 36a. We postulated that two slipped structures, 
formed between homologous regions 1 and 2 and between regions 4 and 5 
respectively, could have contributed to the initial DNA breakage events 
(Figure 36b). However we are unable to explain either the exact positions of 
the deletion breakpoints or the precise mechanism of the insertion by any one 
simple mutational model.  
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Deletion of the DNA fragment may have been mediated by two short direct 
repeats of the form CATW. This implies that non-homologous end joining, a 
pathway that repairs double-strand breaks in DNA, may have been the 
mechanism responsible for this mutation (Seluanov et al., 2004).  
Interestingly, the complement of the deletion hotspot consensus sequence, 
TGRRKM, found in close proximity to the second breakpoint (Figure 36b) may 
have played a role in defining the exact location of this breakpoint. A 6bp copy 
of a GCAGGC fragment resembling the inserted bases was found within 
repeat 4 in the same orientation whilst a 7bp fragment, TGGCCTG 
(complementary to CAGGCCA), was identified at position 441. Although the 
underlying mutational mechanism is unclear, AATCATAC direct repeats, 
spanning the first breakpoint, were found immediately upstream of this 
complementary fragment. 
 
 
Figure 36. A potential mechanism for the origin of the C7 deletion defect. The relative 
positions and orientations of both the Alu and CATW sequence are shown. 
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Neisseria meningitis infections are very serious, and one of the C7D patients 
reported here died of meningitis. The disease also has important sequelae 
and the more infections individuals suffer, the more likely are they to suffer 
long-term complications such as deafness, limb-loss from disseminated intra-
vascular coagulation, or mental impairment (Orren et al., 2006). The deletion 
defect appears to be a relatively common cause of C7 deficiency in Ireland 
and genetic screening is needed to determine the frequency in this 
population. 
 
 
 
 
 
 
 
 
 
88 
 
 
 
 
 
Chapter 5 
The identification of the 
molecular defects in three C8 
deficient patients 
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5.1 Introduction 
 
The molecular defects in three UK resident patients, each of whom had 
presented with recurring episodes of meningitis were determined. The 
patients were referred for molecular screening based on their clinical history 
and tests which demonstrated the complete absence of haemolytic activity. 
The identity of the missing component was tested in a modified CH50 assay 
supplemented to physiological levels with C5, C6, C7, C8, or C9, haemolytic 
activity in the patients‟ serum could be restored to levels comparable to 
normal serum upon addition of pure C8. (data not shown).  
C8 deficiency is less common than deficiency of C6 or C7 and may result 
from lack of the α–γ chain or the β chain.  Deficiency of C8α-γ has been 
predominantly reported amongst Afro-Caribbean people, Hispanic people and 
Japanese (Würzner et al., 1992). C8β deficiency is more common, with the 
majority of cases occurring amongst Caucasian people although C8B 
deficiency has been reported in other areas such as South America (Rosa et 
al., 2004) 
The C8B gene is 38 kb long and contains 12 exons. A single common 
mutation, c.1309C > T, that introduces a premature stop codon (R428X) in 
exon 9, is the causative mutation in approximately 85% of null alleles 
examined in 41 cases of C8β deficiency [Saucedo et al., 1995 and Kaufmann 
et al., 1993]. The remaining 15% are other C>T transitions or single base 
deletions, all of which result in premature termination of translation. These 
mutations are restricted to 4 of the 12 exons (3, 5, 6, and 9). 
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The work described in this chapter includes investigations to identify which C8 
protein was deficient and the molecular investigations to identify the sequence 
variation at the genomic level.  
 
5.2 Methods 
 
5.2.1 Patients  
 
Three UK patients, all male, presented with recurring neisserial meningitis 
infections and during the course of this study consented for whole blood to be 
taken for molecular screening. None of the patients were related and all came 
from different ethnic backgrounds, with one being UK British and two being 
UK Asian. They were aged between 20 and 35 and all experienced their initial 
infection during early childhood. 
 
Patient 1: A UK British Male  
Patient 2: A UK Asian Male  
Patient 3: A UK Asian Male  
. 
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5.3 Confirmation of Missing Component by Western Blotting 
 
Serum samples (30µl, following a 1:10 dilution) were analyzed by non-
denaturing SDS-PAGE  and Western Blotting as described in Experimental 
Methods using a pAb rabbit anti-human C8 (Dako, Ely, Cambridgeshire) at a 
1:2000 dilution as a primary antibody. Protein was detected by incubation with 
an αRbIgG-HRPO conjugated secondary antibody (1/1,000 dilution; Jackson 
ImmunoResearch Laboratories, Philadelphia) for 30 min and the membranes 
developed using ECL reagent.  
A selective exon amplification approach to mutation analysis of C8β 
deficiency was used. Due to the frequency and position of known mutations a 
strategy was implemented in which exons 3; 5; 6; and 9 were amplified and 
sequenced in an initial screen of the C8B gene in these patients.  
DNA was isolated from patient EDTA-blood as described in Experimental 
Methods.  
The genomic DNA isolated from the patient blood samples was assessed for 
quality and quantity using UV spectrometry. Each sample was diluted to 
100ng/µl and used in a PCR to amplify the C8B gene. Each patient was 
screened initially by amplification and sequencing of only those exons in 
which mutations had previously been identified i.e. in exons 3, 5, 6, and 9. 
The PCR products were excised from the agarose gel and purified using a 
geneclean III kit (MP Biomedical, France) and the purified products used in a 
sequencing reaction in both the sense and antisense orientations as 
described in Experimental Methods. The sequencing electropherograms were 
analysed using BIOEDIT software (citation in program) to assess data quality. 
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Sequencing of the remaining exons was performed if no mutations were 
identified by this strategy. 
 
5.4 Gene Nomenclature 
 
The C8B gene is annotated according to current recommendations (Human 
Gene Nomenclature Committee). Nucleotides are numbered using the coding 
reference sequence NM_000066 in which the A of the ATG translation 
initiating codon is numbered +1 
 
5.5 Results 
 
5.5.1 Confirmation of Missing Component by Western Blotting 
 
To determine which subunit of C8 was absent, C8 protein was analyzed by 
non-denaturing SDS-PAGE followed by western blotting using an anti-human 
C8 polyclonal antibody (Figure 37). In normal human serum, C8 is visualized 
as two bands (lane 1). These are the covalently linked α–γ chains (87 kDa) 
and the β chain (64 kDa). Figure 37 shows the result of analysing serum of 
patient 1. There was a clear and specific loss of the β chain (lane 2) in the 
patient‟s serum, confirming deficiency of the C8β subunit in this patient. 
Analysis of the patient‟s serum and comparison with normal human serum 
demonstrated that C8 α–γ chains were present but reduced in amount, as 
previously reported in C8β deficiency (Pallares et al., 1996). The analysis of 
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the remaining patients showed identical results. They were performed by 
other members of laboratory staff and are not shown. 
 
 
 
 
Figure 37. The western blotting of C8β using a polyclonal antibody for both a deficient patient 
(Lane 2) and normal human serum (Lane1) 
 
5.5.2 Genomic Investigations 
 
Each of the exons (3, 5, 6 and 9) were successfully amplified and were the 
correct size from each patient. A representative amplification is shown below 
in figure 38. 
 
 
Figure 38. The amplification of C8B exons 3, 5, 6 and 9 and their flanking intronic sequences. 
The PCR appeared robust during all amplifications. 
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5.5.3 Patient 1 
 
Sequencing results and analysis are shown in figure 39. Sequencing of the 
patient‟s C8B gene identified a heterozygous mutation c.271C>T within exon 
3. This transition causes a nonsense change and introduces a premature stop 
codon at glutamine 91 (p.G91X). No other mutation was identified in this initial 
screen. Sequencing of the remaining exons identified a novel mutation 
caused by a duplication c.1047_1053dup GGCTGTG, in exon 7.  
 
 
Figure 39. Sequencing results for patient 1 showing heterozygosity for both the exon 3 
mutation and the novel c.1047_1053 dupGGCTGTG mutation 
 
Sequencing of parental DNA showed that the patient‟s father carried the novel 
c.1047_1053 dupGGCTGTG mutation, whereas his mother carried the 
c.C271 > T (Q91X) mutation in exon 3, thus demonstrating that these 
mutations are found on separate chromosomes in the patient confirming 
compound heterozygosity (data not shown). 
 
 
 
 
 
95 
 
5.5.4 Patient 2 and 3 
 
Sequencing results and analysis are shown in Figure 40. Sequencing of the 
patients‟ C8B gene demonstrated that they were both homozygous for the 
common mutation, c.1309C > T, that introduces a premature stop codon 
(R428X) in exon 9. 
 
Figure 40. The sequencing results for patient 1 C8B exon 9 in which homozygosity for the 
c.1309C>T defect is shown. Identical results for patient 2 were also observed  
 
5.5.5 Discussion 
 
C8β deficiency is by far the more frequent cause of C8 deficiency in 
Caucasians (Arnold DF et al., 2009) and is commonly caused by a nonsense 
mutation in exon 9 (R428X) together with rarer mutations in exons 3, 5 and 6. 
A strategy of selected exonic amplification to screen the C8B gene for 
causative mutations in C8β deficiency was assessed in 3 patients with C8β 
deficiency. In Patients 2 and 3, sequencing demonstrated that both were 
homozygous for the common c.1309C>T transition supporting the finding that 
it is responsible for most reported cases of C8β deficiency. However Patient 1 
presented differently. This patient was shown to be a compound heterozygote 
of an uncommon, but previously described nonsense mutation, c.271C > T in 
exon 3, (Q91X), (Saucedo et al., 1995) and a novel duplication, c.1047_1053 
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dupGGCTGTG in exon 7. It is likely that this tandem duplication, in common 
with the majority of short insertion mutations, is derived from a slippage-like 
process during DNA replication (Messer and Arndt 2007). It introduces a 
frame shift that results in seven novel amino acid codons (G-C-A-Y-G-H-K) 
immediately downstream of the amino acid L350, followed by a premature 
stop codon. Although either mutation results in the theoretical truncation of the 
C8β protein., no truncated C8 protein was detected by western blotting of this 
patient‟s serum, suggesting that the proteins are either unstable or the 
transcripts containing these mutations are unstable and degraded via the 
nonsense mediated decay pathway.  
These findings confirm that the c.1309C>T mutation is the commonest genetic 
cause for C8β deficiency and that a selected screen for it as a primary 
analysis is appropriate. However, these results also suggest that C8β 
deficiency is more heterogeneous than previously thought. The c.271C>T, 
(p.G91X) mutation has been reported previously as 298C>T in two other 
families (Saucedo et al., 1995) and its presence in a British patient indicates 
that it may be more common than previously considered. Furthermore the 
absence of the c.1309C>T mutation in this patient, indicates that sequencing 
of the entire coding region of the C8B gene may be required in some 
instances. 
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6 Concluding Remarks 
 
Within a clinical research context, an effective screening protocol of common, 
causative mutations should be considered for each gene. This approach 
would make the most efficient use of resources prior to screening the 
remaining exons, UTR‟s and promoter regions. However, as more human 
genomes are sequenced, the number and type of genetic defect are expected 
to increase. Likewise, this is true for complement terminal pathway genes. 
This is of particular concern when new sequence variants are identified where 
the effect of the mutation is not obvious, such as apparently conservative 
amino acid substitutions. Bioinformatics and segregation analyses within 
families can provide supporting evidence, however, experimental verification 
of a causative mutation is often necessary. 
C5 
In cases of C5 deficiency a selected exon approach is appropriate since it is a 
relatively large gene with 41 exons.  Thus, exons 1, 7, 10, 15, 20, 35, 36 and 
40 should be screened for known defects. The functional effect of the C5 exon 
7 sequence variant remains unclear.  
It may be possible this variation interferes with normal C5 exon splicing, and 
verifying this would require minigene experimental data.  
It may be that the exon 7 defect interferes with the structure of the mRNA 
molecule, either causing the molecule to become unstable, aggregate or 
impede translation. It may be possible to perform northern blot analysis to 
examine mRNA size and, through probe hybridisation ability, mRNA structure.  
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Additionally, protein targeting may also be an issue. Defects of protein target 
to the secretion pathway have already been reported in the complement 
terminal pathway (Rameix-Welti et al., 2007).  
Finally, it may be that a molecule is secreted by the gene which lacks C5 
functionality thereby appearing to be deficient. The expression of both C5 and 
the C5 A252T defect recombinant protein in vitro may indicate any inhibition 
of protein production or secretion. 
C7 
An initial selected exon sequencing method for investigating C7 deficiency 
may not be appropriate. Although some founder effects  are known, in which 
defects segregate to specific populations (Fernie et al., 1997b), in general the 
number and geographical distributions of C7 deficiency are too great to allow 
such an approach. Therefore, it is recommended that initially a whole gene 
exon sequencing approach be used. 
The deletion defect reported here was previously proposed following a routine 
failure of PCR amplification and a failure of southern blot probe hybridisation. 
Neither of these methods can be used for clinical diagnosis using DNA 
techniques or for carrier detection, and the duplex PCR method presented 
here meets these requirements. It may be interesting in future studies to 
determine the frequency with which the defect occurs, in particular, the Irish 
population. 
The deletion defect presented here appears to be Alu mediated. Slipped mis-
pairing of Alu sequences during DNA replication is a commonly known 
mechanism of gene rearrangement (Ball et al., 2005). The hypothesis 
discussed here is more complicated, and may illuminate the way in which a 
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failure of the cell‟s normal DNA repair mechanism can be responsible for a 
protein deficiency.  
C8B 
All defects identified in the C8B gene result in either premature stop codons or 
frame shifts. We have confirmed that the 1289C>T mutation is a common 
cause of deficiency, and in cases of C8β deficiency it may be advisable to 
screen for this defect alone in an initial selected exon screen. 
 
There is an intrinsic value in sequence analysis. Taking C5 as an example, 
there are 9 synonomous and 12 non-synonomous sequence variants within 
the coding region of the gene that do not cause C5  deficiency. In addition 
there are over 320 polymorphisms located within the introns. The advent of 
high through-put single genome sequencing will provide greater insight into 
the mechanisms of protein production and the interaction of protein variants 
with other terminal pathway components and complement regulators, thereby 
illuminating variation in the functional capacity of the complement cascade. 
 
Finally, in order to progress from a patient sample to the identification of a 
molecular defect a rigorous process must be employed. Initially DNA or RNA 
technologies may not be appropriate. Regardless of the specific molecular 
defect it is the absence of functional protein that produces a clinical pathology. 
As a first step a haemolytic assay or |ELISA may be employed to identify the 
complement component which is deficient. Further protein techniques such as 
western blotting may resolve whether non functional protein or no protein is 
being produced. 
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It is at this stage that a PCR based investigation of known genomic defects 
may be pursued. The may then require expanding PCR screening to include 
all exons, regions flanking the genes or intronic sequence.  
It may also be prudent, particularly for larger genes such as C5, to examine 
mRNA as the absence of intronic sequence and potential quantification of 
mature mRNA may more rapidly identify novel defects. 
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Appendix 1 – Buffers and Reagents 
 
A number of buffers and reagents were used during this study, the 
compositions of which are listed here. 
 
Lysate Buffer  
 
Used generally for the lysis of cells 
0.1 M NaCl, 50mM Tris pH8, 10 mM EDTA 
For 100 ml, add 2ml of 5 M NaCl, 5ml of 1 M Tris  pH8, 2 ml 0.5M EDTA and 
make up to 100ml with distilled water. This should be autoclaved. 
 
5% Nonfat Dry Milk 
 
The preferred method is that this should be prepared using Marval nonfat Dry 
Milk in TBST. 
 
10% Ammonium Persulfate (APS) Solution  
 
0.12 g APS 
1.2 ml H2O 
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TBST  
 
This can also be made without azide, which can be added back for longer 
incubations such as overnight blocking. 
10mM Tris, 0.15 M NaCl, 8mM sodium azide, 0.05% tween-20, pH 8.0  
Chemical For 4 litres For 500 ml 
Tris  4.84 g  0.61 g Tris 
NaCl  35.06 g  4.38 g NaCl 
NaN3  2.0 g 500 µl 10% NaN3 
Tween-20  2.0 ml  250 µl Tween-20 
Adjust pH to 8.0 with HCl.  
 
SDS PAGE Tank Buffer  
 
25mM Tris, 0.2 M glycine, 0.35% SDS  
Chemical For 4 litres For 500 ml 
Tris 12.11g 1.51 g Tris 
Glycine 57.6 g 7.2 g 
SDS 4.0 g 17.5 ml 10% SDS 
 
Wet blot transfer buffer (3L)    
 
25mM Tris, 0.2M glycine, 20% methanol.  
9.08 g Tris  
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43.24 g glycine  
600 ml methanol  
Make up to 3L with water. 
 
Lower Gel Buffer  
 
For 100 ml:  
18.17 g Tris  
4 ml 10% SDS  
Adjust pH to 8.8 with HCl. Make up to 100 ml with water.  
Upper Gel Buffer  
 
For 100 ml:  
6.06 g Tris  
4 ml 10% SDS  
Adjust pH to 6.8 with HCl. Make up to 100 ml with water.  
SDS 4x  Reducing Sample Buffer  
 
This is made from stock sample buffer which contains0.24 M Tris, 0.24 M 
SDS, 40% glycerol, 20% 2-mercaptoethanol, pH 6.8 
8 ml of stock sample buffer  
2 ml of concentrated 2-mercaptoethanol  
Transfer to 1 ml aliquots and store at -20°C. 
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2x Loading Buffer   
 
This contains 125mM Tris, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 
0.004% bromophenol blue.  
2.5 ml 0.5 M Tris-HCl, pH6.8 
4.0 ml of 10% SDS 
2.0 ml glycerol  
1.0 ml concentrated 2-mercaptoethanol (reducing only)  
0.4 mg bromophenol blue 
Make up to 10 ml with water. Transfer to 1 ml aliquots and store at -20°C. 
Stock Sample Buffer  
 
0.312 M Tris-HCl, 0.346 M SDS, 50% glycerol, pH 6.8  
3.03 g Tris  
8.0 g SDS  
40 ml glycerol  
Adjust pH to 6.8 with HCl. Make up to 80 ml with water.  
ACD 
 
This is an anticoagulation reagent 
 
1.32g of sodium citrate 
0.48g of citric acid  
1.47g of dextrose  
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Add distilled water to 100ml  
The filter sterilize through 0.2um filter  
 
TAE 
 
This is the standard running buffer for agarose gels and the base liquid to 
which agarose is added to make a DNA gel 
 
For 1 litre of 50XTAE stock solution 
242g Tris 
87.1mls of glacial acetic acid 
100mls of 0.5M EDTA pH8.0
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Appendix II – Genomic Primers Details 
 
Sequence Primer Sequence Primer Anneal (°C) 
          
Complement component C5         
AGATCATCTTGTGAGCCCTGTC Promoter F GCTGTTCTCAGAAGTAGCAAG Promoter R 61 
ATGGAATCTCTCAAGTGAGAG 2 F CATCTAATAATCCCACAGTGG 2 R 58 
ACTGAAGGGCTTCGGGCAAAATTT 3 F GAAACCGATCTCCACTCAATTTCA 3 R 58 
GGAATCCCTGAGGATTCTCTT 4 F AGTGTAGTGTGAGGACAGGGT 4 R 58 
GACATGGGTATTTGTCTTC 5 F GCTTCTTCACCAAAAGTTC 5 R 58 
GGAATTTATTAGATCTCCTC 6 F GGAACAGCGAGACTCCA 6 R 54 
CCAGAAAGTCTAGCTGTTTTGCTA 7 F CAATTAGTCCCCAAATCATGGCA 7 R 58 
CTGAATCCTGTTATTGTAACCAT 8 F GTAACTTCTCATCTCTCACCTCT 8 R 58 
GGACTCGGTTATCTACTTTACTTTTGACAC 9 F GACTAAAAAGAAGCAGAGCCCTACTGCC 9 R 58 
ACTCCAACCTGGGCAACGTAG 11 F CACTAGCCAAAACACATGGTC 11 R 60 
GTAATGGAGGGTTTTTTCCCCTTT 12 F TGCTCTTGAAAGTGCTTTGGGAAT 12 R 58 
AGCTCCAGGCTGCATCCTAAAGCACA 13+14 F CTTCCTCCATATCCTAGCCTGGTGGC 13+14 R 60 
GGAATGACTTGTGAAGGCTCTAAATAC 16 F CCTTAGATTAAGGCTATGGCAAATG 16 R 58 
GGTATCCCTTGAGATTCCTTCTAAG 17 F GCATAAAATTACACAAAATTCCCCA 17 R 58 
CCAAAGTGCTGGGATTACAGG 18 F AGTGTATCGCACATAGTTGTG 18 R 58 
GATGAGGTTTTCCTTAATGATGTG 19 F CTACCATTTAAGTCCTGGGTAAAC 19 R 58 
GTGAGCTGAGATCATGCCGC 21 F TTACACTATTGTTTCTCTCC 21 R 58 
TGCTCTGGTCAATATGCAA 22 F CCAGAAGTGGATACTACTGA 22 R 58 
TAATCTGCAAACAGTCTTCC 23 F GCTACTGAACACGGAAGTG 23 R 56 
CTCTAGATGGTTGTCTTC 24 F GTTGAGCCAAAATGCTACAG 24 R 54 
CAGAGCATATGCTTGCTGCC 25 F CCTGAGCAACTGGAGGAATG 25 R 54 
AGATGTGCTGTTCACATTTG 26 F AGATGTGCTGTTCACATTTG 26 R 52 
CCAGCCTGGTCAATATGGTG 27 F GGTGGTCTCTAATATCTATC 27 R 58 
GCCATCCATTTCCATTAGGT 28 F GTTCACTGTCACCACCCA 28 R 58 
TGCATTGGTCATCTTCAGGA 29 F GAGGCCAGATGAGTGTGGTG 29 R 58 
TCATCTCCAGACAATGCTGC 30 F GAGTGGAACAGATGATTTCA 30 R 54 
CAGTGTCTCATCCAGTTACTC 31 F GAGGATAGTTACAAAGATTGC 31 R 58 
GTACACCATTTGTGCTGGAT 32 F CTTGGATGTCAACCTGCTA 32 R 54 
GATTCTGTTCTGACAGGTTC 33 F TTGTATCTTCTGGACATACC 33 R 52 
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Appendix III – PCR additives 
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Appendix IV - DNA recombination motifs 
 
Motif description         Motif sequence(s) 
Vertebrate/plant topoisomerase I consensus cleavage sites    CAT,CTY,GTY, RAT 
Vaccinia topoisomerase I consensus cleavage site     YCCTT  
Vertebrate topoisomerase II consensus cleavage site    RNYNNCNNGYNGKTNYNY 
Drosophila topoisomerase II consensus cleavage site    GTNWAYATTNATNNR 
Heptamer recombination signal        CACAGTG 
Nonamer recombination signal        ACAAAAACC 
Immunoglobulin heavy chain class switch repeats     GAGCT,GGGCT,GGGGT,TGGGG,TGAGC 
Translin target sites         ATGCAG,GCCCWSSW  
Χ element          G C T G G T G G  
H u m a n  h y p e r v a r i a b l e  m i n i s a t e l l i t e  c o r e  s e q u e n c e      G G G C A G G A N G  
H u m a n  m i n i s a t e l l i t e  c o n s e r v e d  s e q u e n c e / w - l i k e  e l e m e n t     G C W G G W G G  
H u m a n  h y p e r v a r i a b l e  m i n i s a t e l l i t e  c o r e  s e q u e n c e      G G A G G T G G G C A G G A R G  
H u m a n  h y p e r v a r i a b l e  m i n i s a t e l l i t e  r e c o m b i n a t i o n  s e q u e n c e    A G A G G T G G G C A G G T G G  
M a r i n e r  t r a n s p o s o n - l i k e  e l e m e n t  ( 3 0 e n d )       G A A A A T G A A G C T A T T T A C C C A G G A   
D e l e t i o n  h o t s p o t  c o n s e n s u s  s e q u e n c e   T G R R K M  
 
